



Date: 07th February 2026

National Stock Exchange of India Limited, Exchange Plaza, 5 th Floor, Plot No. C-1, G Block, Bandra - Kurla Complex, Bandra (East), Mumbai – 400051, Maharashtra, India NSE Scrip Code: SKFINDIA	BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400001, Maharashtra, India BSE Scrip Code: 500472
--	---

Subject: Newspaper Advertisement – Regulation 47 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.

Dear Sir/Madam,

In compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the Financial Results published in the newspapers of Financial Express (all India Edition), Economic Times (Mumbai, Pune, Delhi & Bangalore Edition) in English Language, and in Maharashtra Times (Pune Edition) in Marathi Language.

We request you to take the above information on record and disseminate the same on your respective websites.

This intimation will also be available on the website of the company at <https://www.skf.com/in/investors/skf-india-ltd>.

Thanking you,

Yours faithfully,
SKF India Limited

Mayuri Kulkarni
Company Secretary & Compliance Officer

Encl.: As above.

SKF India Limited

Registered office: Chinchwad, Pune 411 033, Maharashtra, India
Tel: +91 (20) 6611 2500, Fax no: +91 (20) 6611 2396, Web: www.skf.com, Email id: investorIndia@skf.com
CIN: L29130PN1961PLC213113

Decade of Disruption, Century of Change: Build What You Can Defend

Vivek Lall



In every disruptive decade, there is a temptation to chase the newest thing and call it strategy. That approach will fail in the decade ahead. The technologies changing our world are powerful, but power without trust does not scale. The countries and companies that win this century will be the ones that can field advanced capability, protect it, and sustain it in the real world. Artificial intelligence is no longer just a tool for analysis. It is becoming a decision partner.

Autonomy is moving from laboratories to contested aerospace, crowded seas and critical infrastructure. Advanced manufacturing is shrinking timelines that used to be measured in years. Taken together, these shifts are rewriting the economics of security and the economics of growth.

Here is the hard truth: efficiency alone is not resilience. When supply chains are brittle, when data is ungoverned, when standards are unclear, disruption turns vulnerability. The next era will reward builders who treat cybersecurity, export compliance and as-

tion and a shared commitment to rules that protect innovation.

India is positioned to be one of the defining partners of this century. India's strength is not only its scale, it is its depth: engineers, entrepreneurs, research institutions and a growing industrial base that can move from prototype to production. The opportunity now is to connect that capability to global ecosystems in defence, aerospace, space, energy and digital infrastructure, while raising the bar on standards, certification and workforce readiness.

If we want the decade of disruption to become a century of change for the better, we should focus on three practical choices. Invest in frontier technologies. Build the trusted manufacturing and supply networks to sustain them. And establish clear governance so innovation remains an advantage, not a liability.

The future will belong to those who can build boldly and build in a way that can be trusted under pressure.

(Vivek Lall, chief executive, General Atomics Global Corp, will be speaking at ET NOW Global Business Summit 2026 at Taj Palace, New Delhi)

THE TIMES GROUP



sured logistics as part of the design, not paperwork added at the end.

That is why partnerships matter more than press releases. No nation can do everything. But trusted partners can do many things together, faster and at lower risk. Trust is built through performance: predictable delivery, transparent quality, disciplined programme execu-

HC Refers Google Patent Dispute to Mediation

Indu Bhan

New Delhi: The Delhi High Court on Friday referred to mediation a patent infringement case filed by Voicemonk Inc against Google LLC and its group companies.

Voicemonk claims that Google's AI assistant Gemini and its operating system Android are infringing two of Voicemonk's Indian patents.

"Parties referred to mediation before a senior mediator. All efforts will be made by the parties to conclude mediation as soon as possible and not later than four weeks from today [Friday]," Justice Jyoti Singh said.

The court then posted the matter for further hearing to March 13.

Voicemonk had moved court alleging that Google had infringed its patent relating to displaying searched information in one page and learning user behaviour across applications to recommend future actions. Voicemonk also told the court that the parties were already undergoing mediation before filing the case, but Google's offer was not satisfactory, thus leading the matter to court.

Corrigendum

A February 6 story on the quarterly earnings of JSW Cement should have pegged the JSW Group at \$23 billion. The error is regretted.

MADC Moves SC over ₹10-cr Wipro Refund Order

New Delhi: Maharashtra Airport Development Co (MADC) on Friday approached Supreme Court, challenging a Bombay HC order that asked it to refund Wipro ₹10.29 crore that the company paid as advance for allotment of land in Nagpur. MADC had cancelled a letter of acceptance for leasing the land to Wipro and forfeited the advance payment. The HC in August last ruled that retaining the amount would constitute unjust composite project enrichment by MADC. -Indu Bhan

Oil and Natural Gas Corporation Ltd.
Corporate Sports Division
1st Floor, Tower B, Deendayal Urja Bhawan,
5, Nelson Mandela Marg, Vasant Kunj, New Delhi - 110070
Ph. No: 011-26751432/1, e-mail: ongcsports@ongc.co.in

ADVERTISEMENT

Engagement of 30 sportspersons on stipend basis

ONGC invites online applications from meritorious sportspersons in the age group of 18 to 30 years for engagement on stipend in the range from Rs. 30,000/- to Rs. 70,000/- per month in the following Games/Sports:

Games/ Sports	Badminton	Table Tennis	Lawn Tennis	Basketball	Hockey	Kabaddi	Volleyball
Women	1 No.	1 No.	1 No.	-	-	-	-
Men	-	-	1 No.	5 No.	8 No.	7 No.	6 No.

Interested and eligible sportspersons may apply between 07.02.2026 to 14.02.2026 by submitting application in the prescribed format through ONGC's official email address ongcsports@ongc.co.in. Visit www.ongcindia.com for details of stipend scheme and term & conditions. Applications will be accepted only through online mode.

In case any candidate is found to have submitted false or fabricated certificate/document/information, the candidature of such candidate will be rejected with legal action as deemed fit.



Statement of unaudited financial results for the quarter and nine months ended 31 December 2025

S. No.	Particulars	Standalone					
		Quarter ended 31 December 2025	30 September 2025	31 December 2024	31 December 2025	31 December 2024	31 March 2025
1	Total income from operations	26,665.00	17,750.81	22,463.58	60,518.21	50,628.45	72,951.45
2	EBITDA	9,517.07	4,210.59	7,249.25	18,622.67	14,639.99	20,503.66
3	Net Profit before tax	5,998.02	852.70	4,519.13	8,760.64	6,828.27	9,821.06
4	Net profit after tax for the period/year	4,509.18	675.46	3,438.81	6,651.84	5,234.82	7,486.31
5	Total comprehensive income for the period/year	4,532.17	695.05	3,477.23	6,595.08	5,275.51	7,500.04
6	Paid-up equity share capital (face value Rs. 2/- each)	1,672.76	1,672.76	1,672.76	1,672.76	1,672.76	1,672.76
7	Other equity						37,636.78
8	Earnings per share (of Rs. 2/- each) (not annualized for quarters and six months ended)						
(a)	Basic	5.39	0.81	4.11	7.95	6.26	8.95
(b)	Diluted	5.39	0.81	4.11	7.95	6.26	8.95

Notes:

- The above is an extract of the detailed format of quarter and nine months ended 31 December, 2025. Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the Quarter ended are available on the Stock Exchange websites (www.bseindia.com & www.nseindia.com) and on the Company's website www.cantabilinternational.com and also use the following link [NSE- https://www.nseindia.com/get-quotes/equity?symbol=CANTABIL](http://www.nseindia.com/get-quotes/equity?symbol=CANTABIL)
- The financial results for the quarter and nine months ended 31 December 2025 have been reviewed and recommended for approval by the Audit Committee and accordingly approved by the Board of Directors of Cantabil Retail India Limited ("the Company") at their respective meetings held on 06 February 2026. The statutory auditors have carried out a limited review of these results.
- These financial results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- The business activities of the Company predominantly falls within a single primary business segment viz. "Retail", accordingly there are no separate reportable business segments per Ind AS 108 "Operating Segments".
- The Board of Directors has declared an interim dividend @ Rs.0.75/- per equity share (37.50%) of face value of Rs. 2/- per share at their meeting held on 06 February 2026.
- On 21 November 2025, the Government of India notified the four Labour Codes consolidating 29 existing labour laws. The Ministry of Labour & Employment has also issued draft Central Rules and FAQs to help assess the financial impact of these changes. Based on management assessment and the best information available, and in line with the Institute of Chartered Accountants of India (ICAI) guidance, the incremental impact of these changes is not material to the financial results for the quarter and nine month ended 31 December 2025. The Company continues to monitor the finalisation of Central and State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect subsequently on the basis of such developments as needed.
- The previous period/year numbers have been regrouped/reclassified wherever necessary to conform to current period presentation. The impact of such reclassification/regrouping is not material to the financial results.



For Cantabil Retail India Limited
Sd/-
(Vijay Bansal)
Chairman & Managing Director
DIN 01110877

CANTABIL RETAIL INDIA LIMITED

Regd. Office: B-16, Lawrence Road Industrial Area, Delhi - 110035
CIN: L74899DL1989PLC034995, Website: www.cantabilinternational.com

Tel : +91-11-41414188, Email: info@cantabilinternational.com

SKF INDIA LIMITED

CIN: L29130PN1961PLC213113

Registered Address: Chinchwad, Pune 411033 Maharashtra, India

Tel. No.: 91 - 20 66112500 | E-mail: investorIndia@SKF.com | Website: www.skf.com/in/investors/skf-india-ltd

FY25-26: Quarter - October 2025 to December 2025

Revenue Growth (Standalone)	Revenue Growth (Standalone)	PBT Growth (Standalone)	PBT Growth (Standalone)
16.3% QoQ	3.2% YoY	119.1% QoQ	-20.1% YoY

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2025

Particulars	Quarter Ended December 31, 2025* (Unaudited)	Quarter Ended September 30, 2025 (Unaudited)	Quarter Ended December 31, 2024 (Unaudited)	Year Ended March 31, 2025 (Audited)
Revenue from Operations	5,766.4	13,090.6	12,561.0	49,199.2
Net Profit / (Loss) for the Period (Before Tax, Exceptional and/or Extraordinary Items) # ^	964.5	1,663.6	1,470.6	7,632.0
Net Profit / (Loss) for the Period Before Tax (After Exceptional and/or Extraordinary Items) # ^	863.5	1,406.2	1,470.6	7,632.0
Net Profit / (Loss) for the Period After Tax (After Exceptional and/or Extraordinary Items) #	620.0	1,054.9	1,095.0	5,659.1
Total Comprehensive Income for the Period (Comprehensive Profit / (Loss) for the Period (After Tax) and Other Comprehensive Income (After Tax))	611.5	1,080.3	1,059.1	5,579.0
Equity Share Capital	494.4	494.4	494.4	494.4
Reserves (Excluding Revaluation Reserve as Shown in the Audited Balance Sheet of Previous Year)	-	-	-	25,485.3
Earnings Per Share (of Rs. 10/- each) (for Continuing and Discontinued Operations) -				
1. Basic: (Not to be Annualised)	12.5	21.3	22.1	114.5
2. Diluted: (Not to be Annualised)	12.5	21.3	22.1	114.5

Demerger expenses are included as exceptional and/or extraordinary items in the above results ^ Includes share of profit/ (loss) of associates * Effect of Demerger. For more details refer note 4*

For the quarter ended December 31, 2025, the unaudited financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on February 05, 2026.

The above unaudited financial results for the quarter ended December 31, 2025 have been reviewed by the statutory auditors of the Company.

The financial results for the quarter ended December 31, 2025 have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 and read with the Statutory Audit and Disclosure Requirements, 2015, as amended from time to time.

c) The Company manufactures bearings and other related components and it is of the view that it is a single business segment in accordance with Ind AS-108 - 'Operating Segments' notified pursuant to Companies (Accounting Standards) Rules, 2015.

d) On November 2, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020, consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed and disclosed the incremental impact of these changes on the basis of legal advice obtained and the best information available, consistent with guidance provided by the Institute of Chartered Accountants of India. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Company has presented such incremental impact as "Statutory Impact of New Labour Codes" under 'Exceptional Items' in the unaudited financial results for the quarter and period ended December 31, 2025. The incremental impact of basis of Rs. 24 million per annum and Rs. 174.2 million per annum has been included in the financial results of the Company for the quarter and nine months ended December 31, 2025. The Company continues to monitor the finalisation of Central and State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.

ii. During the quarter and nine months ended December 31, 2025, the Company accounted certain demerger expenses for IT Cost, professional services and estimated transfer premium payable to statutory authorities to effect transfer of registration of land acquired under the Scheme, aggregating to Rs. 77 million in unaudited consolidated and standalone financial results, Rs. 334.4 million in unaudited consolidated financial results for the quarter and nine months ended December 31, 2025 and two associates of the Company for the quarter and nine months ended December 31, 2025.

f) The Company has received a certified true copy of the Order dated September 26, 2025, from the Hon'ble National Company Law Tribunal, Mumbai Bench ("NCLT"), approving the Scheme of Arrangement among SKF India Limited ("Demerged Company"), SKF India (Industrial) Limited ("Resulting Company"), and the shareholders and creditors under Section 230-232 of the Companies Act, 2013 and the applicable provisions of the Scheme of Arrangement. The Scheme of Arrangement has been filed with the Registrar of Companies as of October 01, 2025 ("Effective Date"). Following the implementation of the Scheme, the Resulting Company has ceased to be a subsidiary of the Company with effect from October 01, 2025. The Scheme, among other provisions, entails the demerger of the Industrial Undertaking ("Demerged Undertaking") from the Demerged Company into the Resulting Company on a going concern basis. On October 02, 2025, the Resulting Company has allotted 49,437,963 fully paid-up equity shares of the Resulting Company having face value of Rs. 10/- each for every 1 fully paid-up equity share of Rs. 10/- each of the Demerged Company. The liability of the Demerged Company to the Resulting Company in respect of the transfer of the land acquired under the Scheme has been settled by the Demerged Company and the Resulting Company has assumed the liability of the Demerged Company in respect of the land acquired under the Scheme.

g) On account of the demerger, the Company has recognized stamp duty costs, including the estimated transfer premium payable to statutory authorities for effecting the transfer and registration of the land acquired under the Scheme, amounting to Rs. 1,639.2 million. Although the primary responsibility for the payment of the transfer premium rests with the Demerged Company, the Boards of Directors of both entities have mutually agreed that the Resulting Company will bear the entire cost associated with the transfer.

h) The unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 are available on the BSE Limited website (URL: www.bseindia.com) and on the Company's website (URL: www.skf.com.in).

Date of February 05, 2026
Place: Pune

Scan the QR code to view the Financial Results

Scan the QR code to view the outcome of the board meeting

Scan the QR code to view the results on BSE

Scan the QR code to view the results on NSE

Scan the QR code to view the results on BSE

Scan the QR code to view the results on NSE

Scan the QR code to view the results on BSE

Scan the QR code to view the results on NSE

Scan the QR code to view the results on BSE

Scan the QR code to view the results on NSE

Scan the QR code to view the results on BSE

Scan the QR code to view the results on NSE

Scan the QR code to view the results on BSE

Scan the QR code to view the results on NSE

Scan the QR code to view the results on BSE

Scan the QR code to view the results on NSE

Scan the QR code to view the results on BSE

Scan the QR code to view the results on NSE

Scan the QR code to view the results on BSE

Scan the QR code to view the results on NSE


Scan the QR code to view the results on BSE

Scan the QR code to view the results on NSE

Scan the QR code to view the results on BSE

Scan the QR code to view the results on NSE

Scan the QR code to



VIYASH SCIENTIFIC LIMITED (Formerly known as Sequent Scientific Limited)

Regd. Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, Road No. 6, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana, India.
E-mail: investorrelations@sequent.in, E-mail: info@viyash.com, Website: www.sequent.in Tel No.: +91 40 23635000 CIN: L99999TS1985PLC196357

EXTRACT OF THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

(₹ in Lakhs)

Particulars	3 months ended 31-Dec-2025	Preceding 3 months ended 30-Sep-2025	Corresponding 3 months ended in previous period 30-Dec-2024	Year to date for current period ended 31-Dec-2025	Corresponding year to date for previous period 31-Dec-2025	Previous year ended 31-Mar-2025
	Unaudited	Unaudited (Restated) (refer note 2)	Unaudited (Restated) (refer note 2)	Unaudited	Unaudited (Restated) (refer note 2)	Audited (Restated) (refer note 2)
Revenue from operations	8,584.10	8,503.00	7,740.30	25,003.50	22,345.30	30,068.40
Profit before tax and exceptional items	1,143.30	1,040.70	273.70	2,679.90	570.50	947.40
Profit before tax and after exceptional items	730.70	1,023.70	244.80	2,237.80	498.40	131.80
Profit after tax	485.20	729.00	419.40	1,582.70	479.50	157.70
Total comprehensive income / (loss), net of tax	514.30	1,033.70	(123.30)	2,261.50	(156.30)	308.00
Equity share capital	872.20	503.30	500.50	872.20	500.50	500.60
Other equity						23,815.30
Earnings per equity share: (face value of ₹ 2 each) (not annualised)	0.89	1.28	1.04	2.91	1.15	0.54
Basic (in ₹)	0.87	1.26	1.01	2.87	1.13	0.53
Diluted (in ₹)						

SUMMARIZED UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

(₹ in Million)

Particulars	3 months ended 31-Dec-2025	Preceding 3 months ended 30-Sep-2025	Corresponding 3 months ended in previous period 30-Dec-2024	Year to date for current period ended 31-Dec-2025	Corresponding year to date for previous period 31-Dec-2024	Previous year ended 31-Mar-2025
	Unaudited	Unaudited (Restated) (refer note 2)	Unaudited (Restated) (refer note 2)	Unaudited	Unaudited (Restated) (refer note 2)	Audited (Restated) (refer note 2)
Revenue from operations	3,416.40	3,397.50	3,380.50	10,095.70	9,660.20	13,103.40
Profit before tax and exceptional items	518.70	343.70	365.30	1,116.80	865.80	1,306.40
Profit before tax and after exceptional items	106.10	326.70	336.40	674.70	793.70	491.70
Profit / (Loss) after tax	(0.80)	228.40	511.30	400.60	778.60	584.90
Total comprehensive income / (loss), net of tax	(3.30)	229.00	511.00	398.80	791.90	581.70

*1. The above information has been extracted from the detailed financial results for the quarter and nine months ended 31 December 2025 which have been reviewed by the Audit Committee and approved by the Board of Directors and filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. The Board of Directors of the Company at their meeting held on 26 September 2024 have approved the Composite Scheme of Amalgamation (the 'Scheme') amongst the Company, erstwhile Sequent Research Limited (wholly owned subsidiary of the Company), Viyash Life Sciences Private Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, SV Labs Private Limited, Vindhya Organics Private Limited, Genin Life Sciences Private Limited (referred to as 'transferor Companies') in terms of Section 230-232 and other applicable provisions of Companies Act, 2013. The Hon'ble National Company Law Tribunal (NCLT), Hyderabad vide its order dated 18 November 2025 sanctioned the Scheme with an Appointed date of 01 April 2025. The Scheme has become effective on 16 December 2025 upon filing of the certified true copy of the order with the Registrar of Companies Hyderabad. The effect of the Scheme has been given in the financial results for the quarter and nine months ended 31 December 2025. As per the terms of the Scheme, the Company has allotted 18,19,21,827 fully paid-up equity shares of face value of ₹ 2 each, as per the share exchange rate of 56 fully paid-up equity shares of face value of ₹ 2 each of the Company for every 100 fully paid-up equity shares of face value of ₹ 10 each held by eligible shareholder of erstwhile Viyash Life Sciences Private Limited as on the record date. The Company has also allotted 2,03,41,257 warrants under the Scheme to eligible warrant holder of erstwhile Viyash Life Sciences Private Limited as per the Warrant exchange ratio of 56 warrants of the Company for every 100 warrants held in erstwhile Viyash Life Sciences Private Limited and received a consideration of ₹ 925 million during the quarter ended 31 December 2025 (representing 25% on Warrant consideration as per the Scheme). The Company has accounted for the business combination transaction using the 'Pooling of interest method' as given under Appendix C to Ind AS 103, 'Business Combinations of Entities under Common Control', in accordance with the accounting treatment prescribed in the Scheme. Accordingly, the financial results in respect of the preceding / corresponding prior periods have been restated as if the aforesaid business combination had occurred from the beginning of the preceding period i.e. 01 April 2024.
3. The full format of the financial results for the quarter and nine months ended 31 December 2025 are available on the Stock Exchange websites (www.bseindia.com & www.nseindia.com) and Company's website (www.sequent.in).*



For Viyash Scientific Limited
(Formerly known as Sequent Scientific Limited)

Dr. Hari Babu Bodepudi
Managing Director and Gr CEO
DIN 01119687

Hyderabad, 05 February 2026

SMARTLINK HOLDINGS LIMITED

CIN : L26109GA1993PLC001341

Registered office: L-7, Verna Industrial Estate, Verna, Goa - 403 722

Website: www.smartlinkholdings.com

EXTRACT OF STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025

(₹ in Lakhs)

Particulars	3 months ended 31.12.2025 (Unaudited)	3 months ended 30.09.2025 (Unaudited)	3 months ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2025 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
Total income from operations (net)	6,578.68	7,257.01	5,641.50	17,868.71	15,793.41	22,643.64
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	278.46	271.38	181.44	835.76	294.74	533.17
Net Profit / (Loss) for the period (after Exceptional and/or Extraordinary items before tax)	278.46	271.38	181.44	835.76	294.74	533.17
Net Profit / (Loss) after taxes, after extraordinary items	223.92	186.33	254.33	627.76	276.95	660.51
Total Comprehensive income for the period	249.12	179.04	251.74	638.37	261.65	603.89
Equity Share Capital	199.50	199.50	199.50	199.50	199.50	199.50
Reserves (excluding Revaluation Reserve as shown in Balance Sheet of previous year)	N.A.	N.A.	N.A.	N.A.	N.A.	19,432.00
Earnings per share (before extraordinary items) (of ₹ 2/- each)	2.24	1.87	2.55	6.29	2.78	6.62
Basic and Diluted	2.24	1.87	2.55	6.29	2.78	6.62

Key standalone financial information is given below:

Particulars	3 months ended 31.12.2025 (Unaudited)	3 months ended 30.09.2025 (Unaudited)	3 months ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2025 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
Income from Operations	2,518.95	2,852.98	2,961.22	7,249.45	6,751.39	9,696.51
Profit / (Loss) Before Tax	(120.87)	(48.76)	42.88	(151.76)	22.90	(35.46)
Profit / (Loss) After Tax	(81.81)	(38.60)	150.24	(108.47)	79.58	253.68
Total Comprehensive income for the period	(68.21)	(43.09)	150.46	(103.85)	72.70	217.80

Notes :

- The above unaudited Standalone and Consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 06, 2026. The Statutory Auditors have carried out a limited review on the financial results and have expressed an unmodified conclusion thereon.
- The Company is no more a Non-banking financial Company. The Company operates in one primary segment i.e. Networking/IT Products.
- The above is an extract of the detailed format of Quarterly and nine months ended Financial Results filed with Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange websites. The same can be accessed by scanning the QR code provided below.

<https://www.bseindia.com/xml-data/corpfilng/AttachLive/f69264fb-e3d6-4f2a-bb91-65153130bc72.pdf>
https://nsearchives.nseindia.com/corporate/SMARTLINK_06022026131135_Smartlink_Outcome_of_Board_Meeting_06022026.pdf



For and on behalf of the Board

K. R. Naik
Executive Chairman
DIN: 00002013

SKF INDIA LIMITED

CIN: L29130PN1961PLC213113

Registered Address: Chinchwad, Pune 411033 Maharashtra, India

Tel. No.: 91 - 20 66112500 | E-mail: investorIndia@SKF.com | Website: www.skf.com/investors/skf-india-ltd

FY25-26: Quarter - October 2025 to December 2025

Revenue Growth (Standalone)
16.3% QoQ



Revenue Growth (Standalone)
3.2% YoY



PBT Growth (Standalone)
119.1% QoQ



PBT Growth (Standalone)
-20.1% YoY



VIYASH SCIENTIFIC LIMITED (Formerly known as Sequent Scientific Limited)

Regd. Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, Road No. 6, SNN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana, India.
E-mail: investorrelations@sequent.in, E-mail: info@viyash.com, Website: www.sequent.in, Tel No.: +91 40 23635000 CIN: L99999TS1985PLC196357

EXTRACT OF THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

₹ in Lakhs

Particulars	3 months ended 31-Dec-2025	Preceding 3 months ended 30-Sep-2025	Corresponding 3 months ended in previous period 31-Dec-2024	Year to date for current period ended 31-Dec-2025	Corresponding year to date for previous period 31-Dec-2025	Previous year ended 31-Mar-2025
	Unaudited	Unaudited (Restated) (refer note 2)	Unaudited (Restated) (refer note 2)	Unaudited	Unaudited (Restated) (refer note 2)	Audited (Restated) (refer note 2)
Revenue from operations	8,584.10	8,503.00	7,740.30	25,003.50	22,345.30	30,068.40
Profit before tax and exceptional items	1,143.30	1,040.70	273.70	2,679.90	570.50	947.40
Profit before tax and after exceptional items	730.70	1,023.70	244.80	2,237.80	498.40	131.80
Profit after tax	485.20	729.00	419.40	1,582.70	479.50	157.70
Total comprehensive income / (loss), net of tax	514.30	1,033.70	(123.30)	2,261.50	(156.30)	308.00
Equity share capital	872.20	503.30	500.50	872.20	500.50	500.60
Other equity						23,815.30
Earnings per equity share: (face value of ₹ 2 each) (not annualised)	0.89	1.28	1.04	2.91	1.15	0.54
Basic (in ₹)	0.87	1.26	1.01	2.87	1.13	0.53
Diluted (in ₹)						

SUMMARIZED UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

₹ in Lakhs

Particulars	3 months ended 31-Dec-2025	Preceding 3 months ended 30-Sep-2025	Corresponding 3 months ended in previous period 31-Dec-2024	Year to date for current period ended 31-Dec-2025	Corresponding year to date for previous period 31-Dec-2024	Previous year ended 31-Mar-2025
	Unaudited	Unaudited (Restated) (refer note 2)	Unaudited (Restated) (refer note 2)	Unaudited	Unaudited (Restated) (refer note 2)	Audited (Restated) (refer note 2)
Revenue from operations	3,416.40	3,397.50	3,380.50	10,095.70	9,660.20	13,103.40
Profit before tax and exceptional items	518.70	343.70	365.30	1,116.80	865.80	1,306.40
Profit before tax and after exceptional items	106.10	326.70	336.40	674.70	793.70	491.70
Profit / (loss) after tax	(0.80)	228.40	511.30	406.60	778.60	584.90
Total comprehensive income / (loss), net of tax	(3.30)	229.00	511.00	398.80	791.90	581.70

1. The above information has been extracted from the detailed financial results for the quarter and nine months ended 31 December 2025 which have been reviewed by the Audit Committee and approved by the Board of Directors and filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. The Board of Directors of the Company at their meeting held on 26 September 2024 have approved the Composite Scheme of Amalgamation (the 'Scheme') amongst the Company, erstwhile Sequent Research Limited (wholly owned subsidiary of the Company), Viyash Life Sciences Private Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Apco Labs Private Limited, Vindhya Pharma (India) Private Limited, SV Labs Private Limited, Vindhya Organics Private Limited, Genin Life Sciences Private Limited (referred to as 'transferee Companies') in terms of Section 230-232 and other applicable provisions of Companies Act, 2013.

The Hon'ble National Company Law Tribunal (NCLT), Hyderabad vide its order dated 18 November 2025 sanctioned the Scheme with an Appointed date of 01 April 2025. The Scheme has become effective on 16 December 2025 upon filing of the certified true copy of the order with the Registrar of Companies Hyderabad. The effect of the Scheme has been given in the financial results for the quarter and nine months ended 31 December 2025. As per the terms of the Scheme, the Company has allotted 18,19,21,827 fully paid-up equity shares of face value of ₹ 2 each, as per the share exchange ratio of 56 fully paid-up equity shares of face value of ₹ 2 each of the Company to every 100 fully paid-up equity shares of face value of ₹ 10 each held by eligible shareholders of erstwhile Viyash Life Sciences Private Limited as on the record date. The Company has also allotted 2,03,41,257 warrants under the Scheme to eligible warrant holders of erstwhile Viyash Life Sciences Private Limited and received a consideration of ₹ 925 million during the quarter ended 31 December 2025 (representing 25% on Warrant consideration as per the Scheme).

The Company has accounted for the business combination transaction using the 'Pooling of interest method' as given under Appendix C to Ind AS 103, 'Business Combinations of Entities under Common Control', in accordance with the accounting treatment prescribed in the Scheme. Accordingly, the financial results in respect of the preceding / corresponding prior periods have been restated as if the aforesaid business combination had occurred from the beginning of the preceding period i.e. 01 April 2024.

3. The full format of the financial results for the quarter and nine months ended 31 December 2025 are available on the Stock Exchange websites (www.bseindia.com & www.nseindia.com) and Company's website (www.sequent.in).

For Viyash Scientific Limited
(Formerly known as Sequent Scientific Limited)Dr. Hari Babu Bodepudi
Managing Director and Gr CEO
DIN 01119687

Hyderabad, 05 February 2026

SMARTLINK HOLDINGS LIMITED

CIN : L26109GA1993PLC001341

Registered office: L-7, Verna Industrial Estate, Verna, Goa - 403 722

Website: www.smartlinkholdings.comEXTRACT OF STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025

₹ in Lakhs

Particulars	3 months ended 31.12.2025 (Unaudited)	3 months ended 30.09.2025 (Unaudited)	3 months ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2025 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
Total income from operations (net)	6,578.68	7,257.01	5,641.50	17,868.71	15,793.41	22,643.64
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	278.46	271.38	181.44	835.76	294.74	533.17
Net Profit / (Loss) for the period (after Exceptional and/or Extraordinary items before tax)	278.46	271.38	181.44	835.76	294.74	533.17
Net Profit / (Loss) after taxes, after extraordinary items	223.92	186.33	254.33	627.76	276.95	660.51
Total Comprehensive income for the period	249.12	179.04	251.74	638.37	261.65	603.89
Equity Share Capital	199.50	199.50	199.50	199.50	199.50	199.50
Reserves (excluding Revaluation Reserve as shown in Balance Sheet of previous year)	N.A.	N.A.	N.A.	N.A.	N.A.	19,432.00
Earnings per share (before extraordinary items) (of ₹ 2/- each)						
Basic and Diluted	2.24	1.87	2.55	6.29	2.78	6.62
Earnings per share (after extraordinary items) (of ₹ 2/- each)						
Basic and Diluted	2.24	1.87	2.55	6.29	2.78	6.62

Key standalone financial information is given below:

Particulars	3 months ended 31.12.2025 (Unaudited)	3 months ended 30.09.2025 (Unaudited)	3 months ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2025 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
Income from Operations	2,518.95	2,852.98	2,961.22	7,249.45	6,751.39	9,696.51
Profit / (Loss) Before Tax	(120.87)	(48.76)	42.88	(151.76)	22.90	(35.46)
Profit / (Loss) After Tax	(81.81)	(38.60)	150.24	(108.47)	79.58	253.68
Total Comprehensive income for the period	(68.21)	(43.09)	150.46	(103.85)	72.70	217.80

Notes :

- The above unaudited Standalone and Consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 06, 2026. The Statutory Auditors have carried out a limited review on the financial results and have expressed an unmodified conclusion thereon.
- The Company is no more a Non-banking financial Company. The Company operates in one primary segment i.e. Networking/ IT Products.
- The above is an extract of the detailed format of Quarterly and nine months ended Financial Results filed with Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange websites. The same can be accessed by scanning the QR code provided below.

<https://www.bseindia.com/xml-data/corpfilng/AttachLive/f69264fb-e3d6-4f2a-bb91-65153130bc72.pdf>

https://nsearchives.nseindia.com/corporate/SMARTLINK_06022026131135_Smartlink_Outcome_of_Board_Meeting_06022026.pdf



For and on behalf of the Board

K. R. Naik
Executive Chairman
DIN: 00002013

SKF INDIA LIMITED

CIN: L29130PN1961PLC213113

Registered Address: Chinchwad, Pune 411033 Maharashtra, India

Tel. No.: 91 - 20 66112500 | E-mail: investorIndia@SKF.com | Website: www.skf.com/in/investors/skf-india-ltd

FY25-26: Quarter - October 2025 to December 2025

Revenue Growth (Standalone)	Revenue Growth (Standalone)	PBT Growth (Standalone)	PBT Growth (Standalone)
16.3% QoQ	3		



VIYASH SCIENTIFIC LIMITED (Formerly known as Sequent Scientific Limited)

Regd. Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, Road No. 6, SNN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana, India.
E-mail: investorrelations@sequent.in, E-mail: info@viyash.com, Website: www.sequent.in, Tel No.: +91 40 23635000 CIN: L99999TS1985PLC196357

EXTRACT OF THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

₹ in Lakhs

Particulars	3 months ended 31-Dec-2025	Preceding 3 months ended 30-Sep-2025	Corresponding 3 months ended in previous period 31-Dec-2024	Year to date for current period ended 31-Dec-2025	Corresponding year to date for previous period 31-Dec-2025	Previous year ended 31-Mar-2025
	Unaudited	Unaudited (Restated) (refer note 2)	Unaudited (Restated) (refer note 2)	Unaudited	Unaudited (Restated) (refer note 2)	Audited (Restated) (refer note 2)
Revenue from operations	8,584.10	8,503.00	7,740.30	25,003.50	22,345.30	30,068.40
Profit before tax and exceptional items	1,143.30	1,040.70	273.70	2,679.90	570.50	947.40
Profit before tax and after exceptional items	730.70	1,023.70	244.80	2,237.80	498.40	131.80
Profit after tax	485.20	729.00	419.40	1,582.70	479.50	157.70
Total comprehensive income / (loss), net of tax	514.30	1,033.70	(123.30)	2,261.50	(156.30)	308.00
Equity share capital	872.20	503.30	500.50	872.20	500.50	500.60
Other equity						23,815.30
Earnings per equity share: (face value of ₹ 2 each) (not annualised)	0.89	1.28	1.04	2.91	1.15	0.54
Basic (in ₹)	0.87	1.26	1.01	2.87	1.13	0.53
Diluted (in ₹)						

SUMMARIZED UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

₹ in Lakhs

Particulars	3 months ended 31-Dec-2025	Preceding 3 months ended 30-Sep-2025	Corresponding 3 months ended in previous period 31-Dec-2024	Year to date for current period ended 31-Dec-2025	Corresponding year to date for previous period 31-Dec-2024	Previous year ended 31-Mar-2025
	Unaudited	Unaudited (Restated) (refer note 2)	Unaudited (Restated) (refer note 2)	Unaudited	Unaudited (Restated) (refer note 2)	Audited (Restated) (refer note 2)
Revenue from operations	3,416.40	3,397.50	3,380.50	10,095.70	9,660.20	13,103.40
Profit before tax and exceptional items	518.70	343.70	365.30	1,116.80	865.80	1,306.40
Profit before tax and after exceptional items	106.10	326.70	336.40	674.70	793.70	491.70
Profit / (loss) after tax	(0.80)	228.40	511.30	406.60	778.60	584.90
Total comprehensive income / (loss), net of tax	(3.30)	229.00	511.00	398.80	791.90	581.70

1. The above information has been extracted from the detailed financial results for the quarter and nine months ended 31 December 2025 which have been reviewed by the Audit Committee and approved by the Board of Directors and filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. The Board of Directors of the Company at their meeting held on 26 September 2024 have approved the Composite Scheme of Amalgamation (the 'Scheme') amongst the Company, erstwhile Sequent Research Limited (wholly owned subsidiary of the Company), Viyash Life Sciences Private Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Apco Labs Private Limited, Vindhya Pharma (India) Private Limited, SV Labs Private Limited, Vindhya Organics Private Limited, Genin Life Sciences Private Limited (referred to as 'transferee Companies') in terms of Section 230-232 and other applicable provisions of Companies Act, 2013.

The Hon'ble National Company Law Tribunal (NCLT), Hyderabad vide its order dated 18 November 2025 sanctioned the Scheme with an Appointed date of 01 April 2025. The Scheme has become effective on 16 December 2025 upon filing of the certified true copy of the order with the Registrar of Companies Hyderabad. The effect of the Scheme has been given in the financial results for the quarter and nine months ended 31 December 2025. As per the terms of the Scheme, the Company has allotted 18,19,21,827 fully paid-up equity shares of face value of ₹ 2 each, as per the share exchange ratio of 56 fully paid-up equity shares of face value of ₹ 2 each of the Company to every 100 fully paid-up equity shares of face value of ₹ 10 each held by eligible shareholders of erstwhile Viyash Life Sciences Private Limited as on the record date. The Company has also allotted 2,03,41,257 warrants under the Scheme to eligible warrant holders of erstwhile Viyash Life Sciences Private Limited and received a consideration of ₹ 925 million during the quarter ended 31 December 2025 (representing 25% on Warrant consideration as per the Scheme).

The Company has accounted for the business combination transaction using the 'Pooling of interest method' as given under Appendix C to Ind AS 103, 'Business Combinations of Entities under Common Control', in accordance with the accounting treatment prescribed in the Scheme. Accordingly, the financial results in respect of the preceding / corresponding prior periods have been restated as if the aforesaid business combination had occurred from the beginning of the preceding period i.e. 01 April 2024.

3. The full format of the financial results for the quarter and nine months ended 31 December 2025 are available on the Stock Exchange websites (www.bseindia.com & www.nseindia.com) and Company's website (www.sequent.in).

For Viyash Scientific Limited
(Formerly known as Sequent Scientific Limited)Dr. Hari Babu Bodepudi
Managing Director and Gr CEO
DIN 01119687

Hyderabad, 05 February 2026

SMARTLINK HOLDINGS LIMITED

CIN : L26109GA1993PLC001341

Registered office: L-7, Verna Industrial Estate, Verna, Goa - 403 722

Website: www.smartlinkholdings.comEXTRACT OF STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025

₹ in Lakhs

Particulars	3 months ended 31.12.2025 (Unaudited)	3 months ended 30.09.2025 (Unaudited)	3 months ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2025 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
Total income from operations (net)	6,578.68	7,257.01	5,641.50	17,868.71	15,793.41	22,643.64
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	278.46	271.38	181.44	835.76	294.74	533.17
Net Profit / (Loss) for the period (after Exceptional and/or Extraordinary items before tax)	278.46	271.38	181.44	835.76	294.74	533.17
Net Profit / (Loss) after taxes, after extraordinary items	223.92	186.33	254.33	627.76	276.95	660.51
Total Comprehensive income for the period	249.12	179.04	251.74	638.37	261.65	603.89
Equity Share Capital	199.50	199.50	199.50	199.50	199.50	199.50
Reserves (excluding Revaluation Reserve as shown in Balance Sheet of previous year)	N.A.	N.A.	N.A.	N.A.	N.A.	19,432.00
Earnings per share (before extraordinary items) (of ₹ 2/- each)						
Basic and Diluted	2.24	1.87	2.55	6.29	2.78	6.62
Earnings per share (after extraordinary items) (of ₹ 2/- each)						
Basic and Diluted	2.24	1.87	2.55	6.29	2.78	6.62

Key standalone financial information is given below:

Particulars	3 months ended 31.12.2025 (Unaudited)	3 months ended 30.09.2025 (Unaudited)	3 months ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2025 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
Income from Operations	2,518.95	2,852.98	2,961.22	7,249.45	6,751.39	9,696.51
Profit / (Loss) Before Tax	(120.87)	(48.76)	42.88	(151.76)	22.90	(35.46)
Profit / (Loss) After Tax	(81.81)	(38.60)	150.24	(108.47)	79.58	253.68
Total Comprehensive income for the period	(68.21)	(43.09)	150.46	(103.85)	72.70	217.80

Notes :

- The above unaudited Standalone and Consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 06, 2026. The Statutory Auditors have carried out a limited review on the financial results and have expressed an unmodified conclusion thereon.
- The Company is no more a Non-banking financial Company. The Company operates in one primary segment i.e. Networking/ IT Products.
- The above is an extract of the detailed format of Quarterly and nine months ended Financial Results filed with Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange websites. The same can be accessed by scanning the QR code provided below.

<https://www.bseindia.com/xml-data/corpfilng/AttachLive/f69264fb-e3d6-4f2a-bb91-65153130bc72.pdf>

https://nsearchives.nseindia.com/corporate/SMARTLINK_06022026131135_Smartlink_Outcome_of_Board_Meeting_06022026.pdf



For and on behalf of the Board

K. R. Naik
Executive Chairman
DIN: 00002013

SKF INDIA LIMITED

CIN: L29130PN1961PLC213113

Registered Address: Chinchwad, Pune 411033 Maharashtra, India

Tel. No.: 91 - 20 66112500 | E-mail: investorIndia@SKF.com | Website: www.skf.com/in/investors/skf-india-ltd

FY25-26: Quarter - October 2025 to December 2025

Revenue Growth (Standalone)	Revenue Growth (Standalone)	PBT Growth (Standalone)	PBT Growth (Standalone)
16.3% QoQ	3		



VIYASH SCIENTIFIC LIMITED (Formerly known as Sequent Scientific Limited)

Regd. Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, Road No. 6, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana, India.
E-mail: investorrelations@sequent.in, E-mail: info@viyash.com, Website: www.sequent.in Tel No.: +91 40 23635000 CIN: L99999TS1985PLC196357

EXTRACT OF THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

(₹ in Million)

Particulars	3 months ended 31-Dec-2025	Preceding 3 months ended 30-Sep-2025	Corresponding 3 months ended in previous period 30-Dec-2024	Year to date for current period ended 31-Dec-2025	Corresponding year to date for previous period 31-Dec-2025	Previous year ended 31-Mar-2025
	Unaudited	Unaudited (Restated) (refer note 2)	Unaudited (Restated) (refer note 2)	Unaudited	Unaudited (Restated) (refer note 2)	Audited (Restated) (refer note 2)
Revenue from operations	8,584.10	8,503.00	7,740.30	25,003.30	22,345.30	30,068.40
Profit before tax and exceptional items	1,143.30	1,040.70	273.70	2,679.90	570.50	947.40
Profit before tax and after exceptional items	730.70	1,023.70	244.80	2,237.80	498.40	131.80
Profit after tax	485.20	729.00	419.40	1,582.70	479.50	157.70
Total comprehensive income / (loss), net of tax	514.30	1,033.70	(123.30)	2,261.50	(156.30)	308.00
Equity share capital	872.20	503.30	500.50	672.20	500.50	500.60
Other equity						23,815.30
Earnings per equity share: (face value of ₹ 2 each) (not annualised)	0.89	1.28	1.04	2.91	1.15	0.54
Basic (in ₹)	0.87	1.26	1.01	2.87	1.13	0.53
Diluted (in ₹)						

SUMMARIZED UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

(₹ in Million)

Particulars	3 months ended 31-Dec-2025	Preceding 3 months ended 30-Sep-2025	Corresponding 3 months ended in previous period 31-Dec-2024	Year to date for current period ended 31-Dec-2025	Corresponding year to date for previous period 31-Dec-2024	Previous year ended 31-Mar-2025
	Unaudited	Unaudited (Restated) (refer note 2)	Unaudited (Restated) (refer note 2)	Unaudited	Unaudited (Restated) (refer note 2)	Audited (Restated) (refer note 2)
Revenue from operations	3,416.40	3,397.50	3,380.50	10,085.70	9,660.20	13,103.40
Profit before tax and exceptional items	518.70	343.70	365.30	1,116.80	865.80	1,306.40
Profit before tax and after exceptional items	106.10	326.70	336.40	674.70	793.70	491.70
Profit / (loss) after tax	(0.80)	228.40	511.30	400.60	778.60	584.90
Total comprehensive income / (loss), net of tax	(3.30)	229.00	511.00	398.80	791.90	581.70

*1. The above information has been extracted from the detailed financial results for the quarter and nine months ended 31 December 2025 which have been reviewed by the Audit Committee and approved by the Board of Directors and filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. The Board of Directors of the Company at their meeting held on 26 September 2024 have approved the Composite Scheme of Amalgamation (the 'Scheme') amongst the Company, erstwhile Sequent Research Limited (wholly owned subsidiary of the Company), Viyash Life Sciences Private Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, SV Labs Private Limited, Vindhya Organics Private Limited, Genia Life Sciences Private Limited (referred to as 'transferor Companies') in terms of Section 230-232 and other applicable provisions of Companies Act, 2013.
The Hon'ble National Company Law Tribunal (NCLT), Hyderabad vide its order dated 18 November 2025 sanctioned the Scheme with an Appointed date of 01 April 2025. The Scheme has become effective on 16 December 2025 upon filing of the certified true copy of the order with the Registrar of Companies Hyderabad. The effect of the Scheme has been given in the financial results for the quarter and nine months ended 31 December 2025. As per the terms of the Scheme, the Company has allotted 18,19,21,827 fully paid-up equity shares of face value of ₹ 2 each, as per the share exchange ratio of 56 fully paid-up equity shares of face value of ₹ 2 each of the Company for every 100 fully paid-up equity shares of face value of ₹ 10 each held by eligible shareholders of erstwhile Viyash Life Sciences Private Limited as on the record date. The Company has also allotted 2,03,41,257 warrants under the Scheme to eligible warrant holder of erstwhile Viyash Life Sciences Private Limited as per the Warrant exchange ratio of 56 warrants of the Company for every 100 warrants held in erstwhile Viyash Life Sciences Private Limited and received a consideration of ₹ 925 million during the quarter ended 31 December 2025 (representing 25% on Warrant consideration as per the Scheme).
The Company has accounted for the business combination transaction using the 'Pooling of interest method' as given under Appendix C to Ind AS 103, 'Business Combinations of Entities under Common Control', in accordance with the accounting treatment prescribed in the Scheme. Accordingly, the financial results in respect of the preceding / corresponding prior periods have been restated as if the aforesaid business combination had occurred from the beginning of the preceding period i.e. 01 April 2024.
3. The full format of the financial results for the quarter and nine months ended 31 December 2025 are available on the Stock Exchange websites (www.bseindia.com & www.nseindia.com) and Company's website (www.sequent.in).

For Viyash Scientific Limited
(Formerly known as Sequent Scientific Limited)Dr. Hari Babu Bodepudi
Managing Director and Gr CEO
DIN 01119687

Hyderabad, 05 February 2026

SMARTLINK HOLDINGS LIMITED

CIN : L26109GA1993PLC001341

Registered office: L-7, Verna Industrial Estate, Verna, Goa - 403 722

Website: www.smartlinkholdings.comEXTRACT OF STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025

(₹ in Lakhs)

Particulars	3 months ended 31.12.2025 (Unaudited)	3 months ended 30.09.2025 (Unaudited)	3 months ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2025 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
Total income from operations (net)	6,578.68	7,257.01	5,641.50	17,868.71	15,793.41	22,643.64
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	278.46	271.38	181.44	835.76	294.74	533.17
Net Profit / (Loss) for the period (after Exceptional and/or Extraordinary items before tax)	278.46	271.38	181.44	835.76	294.74	533.17
Net Profit / (Loss) after taxes, after extraordinary items	223.92	186.33	254.33	627.76	276.95	660.51
Total Comprehensive income for the period	249.12	179.04	251.74	638.37	261.65	603.89
Equity Share Capital	199.50	199.50	199.50	199.50	199.50	199.50
Reserves (excluding Revaluation Reserve as shown in Balance Sheet of previous year)	N.A.	N.A.	N.A.	N.A.	N.A.	19,432.00
Earnings per share (before extraordinary items) (of ₹ 2/- each)	2.24	1.87	2.55	6.29	2.78	6.62
Basic and Diluted	2.24	1.87	2.55	6.29	2.78	6.62
Earnings per share (after extraordinary items) (of ₹ 2/- each)	2.24	1.87	2.55	6.29	2.78	6.62
Basic and Diluted	2.24	1.87	2.55	6.29	2.78	6.62

Key standalone financial information is given below:

Particulars	3 months ended 31.12.2025 (Unaudited)	3 months ended 30.09.2025 (Unaudited)	3 months ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2025 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
Income from Operations	2,518.95	2,852.98	2,961.22	7,249.45	6,751.39	9,696.51
Profit / (Loss) Before Tax	(120.87)	(48.76)	42.88	(151.76)	22.90	(35.46)
Profit / (Loss) After Tax	(81.81)	(38.60)	150.24	(108.47)	79.58	253.68
Total Comprehensive income for the period	(68.21)	(43.09)	150.46	(103.85)	72.70	217.80

Notes :

- The above unaudited Standalone and Consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 06, 2026. The Statutory Auditors have carried out a limited review on the financial results and have expressed an unmodified conclusion thereon.
- The Company is no more a Non-banking financial Company. The Company operates in one primary segment i.e. Networking/ IT Products.
- The above is an extract of the detailed format of Quarterly and nine months ended Financial Results filed with Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange websites. The same can be accessed by scanning the QR code provided below.

<https://www.bseindia.com/xml-data/corpfilng/AttachLive/f69264fb-e3d6-4f2a-bb91-65153130bc72.pdf>
https://nsearchives.nseindia.com/corporate/SMARTLINK_06022026131135_Smartlink_Outcome_of_Board_Meeting_06022026.pdf



For and on behalf of the Board

K. R. Naik
Executive Chairman
DIN: 00002013

SKF INDIA LIMITED

CIN: L29130PN1961PLC213113

Registered Address: Chinchwad, Pune 411033 Maharashtra, India

Tel. No.: 91 - 20 66112500 | E-mail: investorIndia@SKF.com | Website: www.skf.com/in/investors/skf-india-ltd

FY25-26: Quarter - October - December 2025 to December 2025

Revenue Growth (Standalone)	Revenue Growth (Standalone)	PBT Growth (Standalone)	PBT Growth (Standalone)
16.3% QoQ	3.2% YoY	119.1% QoQ	-20.1% YoY</th



VIYASH SCIENTIFIC LIMITED (Formerly known as Sequent Scientific Limited)

Regd. Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, Road No. 6, SNN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana, India.
E-mail: investorrelations@sequent.in, E-mail: info@viyash.com, Website: www.sequent.in Tel No.: +91 40 23635000 CIN: L99999TS1985PLC196357

EXTRACT OF THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

₹ in Lakhs

Particulars	3 months ended 31-Dec-2025	Preceding 3 months ended 30-Sep-2025	Corresponding 3 months ended in previous period 30-Dec-2024	Year to date for current period ended 31-Dec-2025	Corresponding year to date for previous period 31-Dec-2025	Previous year ended 31-Mar-2025
	Unaudited	Unaudited (Restated) (refer note 2)	Unaudited (Restated) (refer note 2)	Unaudited	Unaudited (Restated) (refer note 2)	Audited (Restated) (refer note 2)
Revenue from operations	8,584.10	8,503.00	7,740.30	25,003.50	22,345.30	30,068.40
Profit before tax and exceptional items	1,143.30	1,040.70	273.70	2,679.90	570.50	947.40
Profit before tax and after exceptional items	730.70	1,023.70	244.80	2,237.80	498.40	131.80
Profit after tax	485.20	729.00	419.40	1,582.70	479.50	157.70
Total comprehensive income / (loss), net of tax	514.30	1,033.70	(123.30)	2,261.50	(156.30)	308.00
Equity share capital	872.20	503.30	500.50	872.20	500.50	500.60
Other equity						23,815.30
Earnings per equity share: (face value of ₹ 2 each) (not annualised)	0.89	1.28	1.04	2.91	1.15	0.54
Basic (in ₹)	0.87	1.26	1.01	2.87	1.13	0.53
Diluted (in ₹)						

SUMMARIZED UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

₹ in Lakhs

Particulars	3 months ended 31-Dec-2025	Preceding 3 months ended 30-Sep-2025	Corresponding 3 months ended in previous period 31-Dec-2024	Year to date for current period ended 31-Dec-2025	Corresponding year to date for previous period 31-Dec-2024	Previous year ended 31-Mar-2025
	Unaudited	Unaudited (Restated) (refer note 2)	Unaudited (Restated) (refer note 2)	Unaudited	Unaudited (Restated) (refer note 2)	Audited (Restated) (refer note 2)
Revenue from operations	3,416.40	3,397.50	3,380.50	10,095.70	9,660.20	13,103.40
Profit before tax and exceptional items	518.70	343.70	365.30	1,116.80	865.80	1,306.40
Profit before tax and after exceptional items	106.10	326.70	336.40	674.70	793.70	491.70
Profit / (loss) after tax	(0.80)	228.40	511.30	406.60	778.60	584.90
Total comprehensive income / (loss), net of tax	(3.30)	229.00	511.00	398.80	791.90	581.70

*1. The above information has been extracted from the detailed financial results for the quarter and nine months ended 31 December 2025 which have been reviewed by the Audit Committee and approved by the Board of Directors and filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. The Board of Directors of the Company at their meeting held on 26 September 2024 have approved the Composite Scheme of Amalgamation (the 'Scheme') amongst the Company, erstwhile Sequent Research Limited (wholly owned subsidiary of the Company), Viyash Life Sciences Private Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Apocure Labs Private Limited, Vindhya Pharma (India) Private Limited, SV Labs Private Limited, Vindhya Organics Private Limited, Genin Life Sciences Private Limited (referred to as 'transferee Companies') in terms of Section 230-232 and other applicable provisions of Companies Act, 2013.

The Hon'ble National Company Law Tribunal (NCLT), Hyderabad vide its order dated 18 November 2025 sanctioned the Scheme with an Appointed date of 01 April 2025. The Scheme has become effective on 16 December 2025 upon filing of the certified true copy of the order with the Registrar of Companies Hyderabad. The effect of the Scheme has been given in the financial results for the quarter and nine months ended 31 December 2025. As per the terms of the Scheme, the Company has allotted 18,19,21,827 fully paid-up equity shares of face value of ₹ 2 each, as per the share exchange ratio of 56 fully paid-up equity shares of face value of ₹ 2 each of the Company to 100 fully paid-up equity shares of face value of ₹ 10 each held by eligible shareholders of erstwhile Viyash Life Sciences Private Limited as on the record date. The Company has also allotted 2,03,41,257 warrants under the Scheme to eligible warrant holders of erstwhile Viyash Life Sciences Private Limited and received a consideration of ₹ 925 million during the quarter ended 31 December 2025 (representing 25% on Warrant consideration as per the Scheme).

The Company has accounted for the business combination transaction using the 'Pooling of interest method' as given under Appendix C to Ind AS 103, 'Business Combinations of Entities under Common Control', in accordance with the accounting treatment prescribed in the Scheme. Accordingly, the financial results in respect of the preceding / corresponding prior periods have been restated as if the aforesaid business combination had occurred from the beginning of the preceding period i.e. 01 April 2024.

3. The full format of the financial results for the quarter and nine months ended 31 December 2025 are available on the Stock Exchange websites (www.bseindia.com & www.nseindia.com) and Company's website (www.sequent.in).

For Viyash Scientific Limited
(Formerly known as Sequent Scientific Limited)Dr. Hari Babu Bodepudi
Managing Director and Gr CEO
DIN 01119687

Hyderabad, 05 February 2026

SMARTLINK HOLDINGS LIMITED

CIN : L26109GA1993PLC001341

Registered office: L-7, Verna Industrial Estate, Verna, Goa - 403 722

Website: www.smartlinkholdings.comEXTRACT OF STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025

₹ in Lakhs

Particulars	3 months ended 31.12.2025 (Unaudited)	3 months ended 30.09.2025 (Unaudited)	3 months ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2025 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
Total income from operations (net)	6,578.68	7,257.01	5,641.50	17,868.71	15,793.41	22,643.64
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	278.46	271.38	181.44	835.76	294.74	533.17
Net Profit / (Loss) for the period (after Exceptional and/or Extraordinary items before tax)	278.46	271.38	181.44	835.76	294.74	533.17
Net Profit / (Loss) after taxes, after extraordinary items	223.92	186.33	254.33	627.76	276.95	660.51
Total Comprehensive income for the period	249.12	179.04	251.74	638.37	261.65	603.89
Equity Share Capital	199.50	199.50	199.50	199.50	199.50	199.50
Reserves (excluding Revaluation Reserve as shown in Balance Sheet of previous year)	N.A.	N.A.	N.A.	N.A.	N.A.	19,432.00
Earnings per share (before extraordinary items) (of ₹ 2/- each)						
Basic and Diluted	2.24	1.87	2.55	6.29	2.78	6.62
Earnings per share (after extraordinary items) (of ₹ 2/- each)						
Basic and Diluted	2.24	1.87	2.55	6.29	2.78	6.62

Key standalone financial information is given below:

Particulars	3 months ended 31.12.2025 (Unaudited)	3 months ended 30.09.2025 (Unaudited)	3 months ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2025 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
Income from Operations	2,518.95	2,852.98	2,961.22	7,249.45	6,751.39	9,696.51
Profit / (Loss) Before Tax	(120.87)	(48.76)	42.88	(151.76)	22.90	(35.46)
Profit / (Loss) After Tax	(81.81)	(38.60)	150.24	(108.47)	79.58	253.68
Total Comprehensive income for the period	(68.21)	(43.09)	150.46	(103.85)	72.70	217.80

Notes :

- The above unaudited Standalone and Consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 06, 2026. The Statutory Auditors have carried out a limited review on the financial results and have expressed an unmodified conclusion thereon.
- The Company is no more a Non-banking financial Company. The Company operates in one primary segment i.e. Networking/ IT Products.
- The above is an extract of the detailed format of Quarterly and nine months ended Financial Results filed with Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange websites. The same can be accessed by scanning the QR code provided below.

<https://www.bseindia.com/xml-data/corpfilng/AttachLive/f69264fb-e3d6-4f2a-bb91-65153130bc72.pdf>

https://nsearchives.nseindia.com/corporate/SMARTLINK_06022026131135_Smartlink_Outcome_of_Board_Meeting_06022026.pdf



For and on behalf of the Board

K. R. Naik
Executive Chairman
DIN: 00002013

SKF INDIA LIMITED

CIN: L29130PN1961PLC213113

Registered Address: Chinchwad, Pune 411033 Maharashtra, India

Tel. No.: 91 - 20 66112500 | E-mail: investorIndia@SKF.com | Website: www.skf.com/in/investors/skf-india-ltd

FY25-26: Quarter - October 2025 to December 2025

Revenue Growth (Standalone)	Revenue Growth (Standalone)	PBT Growth (Standalone)	PBT Growth (Standalone)
16.3% QoQ	3.		



VIYASH SCIENTIFIC LIMITED (Formerly known as Sequent Scientific Limited)

Regd. Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, Road No. 6, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana, India.
E-mail: investorrelations@sequent.in, E-mail: info@viyash.com, Website: www.sequent.in Tel No.: +91 40 23635000 CIN: L99999TS1985PLC196357

EXTRACT OF THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

₹ in Lakhs)

Particulars	3 months ended 31-Dec-2025	Preceding 3 months ended 30-Sep-2025	Corresponding 3 months ended in previous period 30-Dec-2024	Year to date for current period ended 31-Dec-2025	Corresponding year to date for previous period 31-Dec-2025	Previous year ended 31-Mar-2025
	Unaudited	Unaudited (Restated) (refer note 2)	Unaudited (Restated) (refer note 2)	Unaudited	Unaudited (Restated) (refer note 2)	Audited (Restated) (refer note 2)
Revenue from operations	8,584.10	8,503.00	7,740.30	25,003.50	22,345.30	30,068.40
Profit before tax and exceptional items	1,143.30	1,040.70	273.70	2,679.90	570.50	947.40
Profit before tax and after exceptional items	730.70	1,023.70	244.80	2,237.80	498.40	131.80
Profit after tax	485.20	729.00	419.40	1,582.70	479.50	157.70
Total comprehensive income / (loss), net of tax	514.30	1,033.70	(123.30)	2,261.50	(156.30)	308.00
Equity share capital	872.20	503.30	500.50	872.20	500.50	500.60
Other equity						23,815.30
Earnings per equity share: (face value of ₹ 2 each) (not annualised)	0.89	1.28	1.04	2.91	1.15	0.54
Basic (in ₹)	0.87	1.26	1.01	2.87	1.13	0.53
Diluted (in ₹)						

SUMMARIZED UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

₹ in Million)

Particulars	3 months ended 31-Dec-2025	Preceding 3 months ended 30-Sep-2025	Corresponding 3 months ended in previous period 31-Dec-2024	Year to date for current period ended 31-Dec-2025	Corresponding year to date for previous period 31-Dec-2024	Previous year ended 31-Mar-2025
	Unaudited	Unaudited (Restated) (refer note 2)	Unaudited (Restated) (refer note 2)	Unaudited	Unaudited (Restated) (refer note 2)	Audited (Restated) (refer note 2)
Revenue from operations	3,416.40	3,397.50	3,380.50	10,095.70	9,660.20	13,103.40
Profit before tax and exceptional items	518.70	343.70	365.30	1,116.80	865.80	1,306.40
Profit before tax and after exceptional items	106.10	326.70	336.40	674.70	793.70	491.70
Profit / (loss) after tax	(0.80)	228.40	511.30	400.60	778.60	584.90
Total comprehensive income / (loss), net of tax	(3.30)	229.00	511.00	398.80	791.90	581.70

1. The above information has been extracted from the detailed financial results for the quarter and nine months ended 31 December 2025 which have been reviewed by the Audit Committee and approved by the Board of Directors and filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. The Board of Directors of the Company at their meeting held on 26 September 2024 have approved the Composite Scheme of Amalgamation (the 'Scheme') amongst the Company, erstwhile Sequent Research Limited (wholly owned subsidiary of the Company), Viyash Life Sciences Private Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Appure Labs Private Limited, Vindhya Pharma (India) Private Limited, SV Labs Private Limited, Vindhya Organics Private Limited, Genin Life Sciences Private Limited (referred to as 'transferee Companies') in terms of Section 230-232 and other applicable provisions of Companies Act, 2013.

The Hon'ble National Company Law Tribunal (NCLT), Hyderabad vide its order dated 18 November 2025 sanctioned the Scheme with an Appointed date of 01 April 2025. The Scheme has become effective on 16 December 2025 upon filing of the certified true copy of the order with the Registrar of Companies Hyderabad. The effect of the Scheme has been given in the financial results for the quarter and nine months ended 31 December 2025. As per the terms of the Scheme, the Company has allotted 18,19,21,827 fully paid-up equity shares of face value of ₹ 2 each, as per the share exchange ratio of 56 fully paid-up equity shares of face value of ₹ 2 each of the Company for every 100 fully paid-up equity shares of face value of ₹ 10 each held by eligible shareholders of erstwhile Viyash Life Sciences Private Limited as on the record date. The Company has also allotted 2,03,41,257 warrants under the Scheme to eligible warrant holders of erstwhile Viyash Life Sciences Private Limited as per the Warrant exchange ratio of 56 warrants of the Company for every 100 warrants held in erstwhile Viyash Life Sciences Private Limited and received a consideration of ₹ 925 million during the quarter ended 31 December 2025 (representing 25% on Warrant consideration as per the Scheme).

The Company has accounted for the business combination transaction using the 'Pooling of interest method' as given under Appendix C to Ind AS 103, 'Business Combinations of Entities under Common Control', in accordance with the accounting treatment prescribed in the Scheme. Accordingly, the financial results in respect of the preceding / corresponding prior periods have been restated as if the aforesaid business combination had occurred from the beginning of the preceding period i.e. 01 April 2024.

3. The full format of the financial results for the quarter and nine months ended 31 December 2025 are available on the Stock Exchange websites (www.bseindia.com & www.nseindia.com) and Company's website (www.sequent.in)."

For Viyash Scientific Limited
(Formerly known as Sequent Scientific Limited)Dr. Hari Babu Bodepudi
Managing Director and Gr CEO
DIN 01119687

Hyderabad, 05 February 2026

SMARTLINK HOLDINGS LIMITED

CIN : L26109GA1993PLC001341

Registered office: L-7, Verna Industrial Estate, Verna, Goa - 403 722

Website: www.smartlinkholdings.com

EXTRACT OF STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025

(₹ in Lakhs)

Particulars	3 months ended 31.12.2025 (Unaudited)	3 months ended 30.09.2025 (Unaudited)	3 months ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2025 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
Total income from operations (net)	6,578.68	7,257.01	5,641.50	17,868.71	15,793.41	22,643.64
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	278.46	271.38	181.44	835.76	294.74	533.17
Net Profit / (Loss) for the period (after Exceptional and/or Extraordinary items before tax)	278.46	271.38	181.44	835.76	294.74	533.17
Net Profit / (Loss) after taxes, after extraordinary items	223.92	186.33	254.33	627.76	276.95	660.51
Total Comprehensive income for the period	249.12	179.04	251.74	638.37	261.65	603.89
Equity Share Capital	199.50	199.50	199.50	199.50	199.50	199.50
Reserves (excluding Revaluation Reserve as shown in Balance Sheet of previous year)	N.A.	N.A.	N.A.	N.A.	N.A.	19,432.00
Earnings per share (before extraordinary items) (of ₹ 2/- each)						
Basic and Diluted	2.24	1.87	2.55	6.29	2.78	6.62
Earnings per share (after extraordinary items) (of ₹ 2/- each)						
Basic and Diluted	2.24	1.87	2.55	6.29	2.78	6.62

Key standalone financial information is given below:

Particulars	3 months ended 31.12.2025 (Unaudited)	3 months ended 30.09.2025 (Unaudited)	3 months ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2025 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
Income from Operations	2,518.95	2,852.98	2,961.22	7,249.45	6,751.39	9,696.51
Profit / (Loss) Before Tax	(120.87)	(48.76)	42.88	(151.76)	22.90	(35.46)
Profit / (Loss) After Tax	(81.81)	(38.60)	150.24	(108.47)	79.58	253.68
Total Comprehensive income for the period	(68.21)	(43.09)	150.46	(103.85)	72.70	217.80

Notes :

- The above unaudited Standalone and Consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 06, 2026. The Statutory Auditors have carried out a limited review on the financial results and have expressed an unmodified conclusion thereon.
- The Company is no more a Non-banking financial Company. The Company operates in one primary segment i.e. Networking/IT Products.
- The above is an extract of the detailed format of Quarterly and nine months ended Financial Results filed with Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange websites. The same can be accessed by scanning the QR code provided below.

https://www.bseindia.com/xml-data/corpfilng/AttachLive/f69264b-e3d6-4f2a-bb91-65153130bc72.pdf
https://nsearchives.nseindia.com/corporate/SMARTLINK_06022026131135_Smartlink_Outcome_of_Board_Meeting_06022026.pdf



For and on behalf of the Board

K. R. Naik
Executive Chairman
DIN: 00002013

SKF INDIA LIMITED

CIN: L29130PN1961PLC213113

Registered Address: Chinchwad, Pune 411033 Maharashtra, India

Tel. No.: 91 - 20 66112500 | E-mail: investorIndia@SKF.com | Website: www.skf.com/in/investors/skf-india-ltd

FY25-26: Quarter - October - December 2025 to December 2025

Revenue Growth (Standalone)	Revenue Growth (Standalone)	PBT Growth (Standalone)	PBT Growth (Standalone)
16.3% QoQ	3.2% YoY	119.1% QoQ	-20.1% YoY



VIYASH SCIENTIFIC LIMITED (Formerly known as Sequent Scientific Limited)

Regd. Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, Road No. 6, SNN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana, India.
E-mail: investorrelations@sequent.in, E-mail: info@viyash.com, Website: www.sequent.in Tel No.: +91 40 23635000 CIN: L99999TS1985PLC196357

EXTRACT OF THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

₹ in Lakhs

Particulars	3 months ended 31-Dec-2025	Preceding 3 months ended 30-Sep-2025	Corresponding 3 months ended in previous period 30-Dec-2024	Year to date for current period ended 31-Dec-2025	Corresponding year to date for previous period 31-Dec-2025	Previous year ended 31-Mar-2025
	Unaudited	Unaudited (Restated) (refer note 2)	Unaudited (Restated) (refer note 2)	Unaudited	Unaudited (Restated) (refer note 2)	Audited (Restated) (refer note 2)
Revenue from operations	8,584.10	8,503.00	7,740.30	25,003.50	22,345.30	30,068.40
Profit before tax and exceptional items	1,143.30	1,040.70	273.70	2,679.90	570.50	947.40
Profit before tax and after exceptional items	730.70	1,023.70	244.80	2,237.80	498.40	131.80
Profit after tax	485.20	729.00	419.40	1,582.70	479.50	157.70
Total comprehensive income / (loss), net of tax	514.30	1,033.70	(123.30)	2,261.50	(156.30)	308.00
Equity share capital	872.20	503.30	500.50	872.20	500.50	500.60
Other equity						23,815.30
Earnings per equity share: (face value of ₹ 2 each) (not annualised)	0.89	1.28	1.04	2.91	1.15	0.54
Basic (in ₹)	0.87	1.26	1.01	2.87	1.13	0.53
Diluted (in ₹)						

SUMMARIZED UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

₹ in Lakhs

Particulars	3 months ended 31-Dec-2025	Preceding 3 months ended 30-Sep-2025	Corresponding 3 months ended in previous period 31-Dec-2024	Year to date for current period ended 31-Dec-2025	Corresponding year to date for previous period 31-Dec-2024	Previous year ended 31-Mar-2025
	Unaudited	Unaudited (Restated) (refer note 2)	Unaudited (Restated) (refer note 2)	Unaudited	Unaudited (Restated) (refer note 2)	Audited (Restated) (refer note 2)
Revenue from operations	3,416.40	3,397.50	3,380.50	10,095.70	9,660.20	13,103.40
Profit before tax and exceptional items	518.70	343.70	365.30	1,116.80	865.80	1,306.40
Profit before tax and after exceptional items	106.10	326.70	336.40	674.70	793.70	491.70
Profit / (loss) after tax	(0.80)	228.40	511.30	406.60	778.60	584.90
Total comprehensive income / (loss), net of tax	(3.30)	229.00	511.00	398.80	791.90	581.70

*1. The above information has been extracted from the detailed financial results for the quarter and nine months ended 31 December 2025 which have been reviewed by the Audit Committee and approved by the Board of Directors and filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. The Board of Directors of the Company at their meeting held on 26 September 2024 have approved the Composite Scheme of Amalgamation (the 'Scheme') amongst the Company, erstwhile Sequent Research Limited (wholly owned subsidiary of the Company), Viyash Life Sciences Private Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Apocure Labs Private Limited, Vindhya Pharma (India) Private Limited, SV Labs Private Limited, Vindhya Organics Private Limited, Genin Life Sciences Private Limited (referred to as 'transferee Companies') in terms of Section 230-232 and other applicable provisions of Companies Act, 2013.

The Hon'ble National Company Law Tribunal (NCLT), Hyderabad vide its order dated 18 November 2025 sanctioned the Scheme with an Appointed date of 01 April 2025. The Scheme has become effective on 16 December 2025 upon filing of the certified true copy of the order with the Registrar of Companies Hyderabad. The effect of the Scheme has been given in the financial results for the quarter and nine months ended 31 December 2025. As per the terms of the Scheme, the Company has allotted 18,19,21,827 fully paid-up equity shares of face value of ₹ 2 each, as per the share exchange ratio of 56 fully paid-up equity shares of face value of ₹ 2 each of the Company to every 100 fully paid-up equity shares of face value of ₹ 10 each held by eligible shareholders of erstwhile Viyash Life Sciences Private Limited as on the record date. The Company has also allotted 2,03,41,257 warrants under the Scheme to eligible warrant holders of erstwhile Viyash Life Sciences Private Limited and received a consideration of ₹ 925 million during the quarter ended 31 December 2025 (representing 25% on Warrant consideration as per the Scheme).

The Company has accounted for the business combination transaction using the 'Pooling of interest method' as given under Appendix C to Ind AS 103, 'Business Combinations of Entities under Common Control', in accordance with the accounting treatment prescribed in the Scheme. Accordingly, the financial results in respect of the preceding / corresponding prior periods have been restated as if the aforesaid business combination had occurred from the beginning of the preceding period i.e. 01 April 2024.

3. The full format of the financial results for the quarter and nine months ended 31 December 2025 are available on the Stock Exchange websites (www.bseindia.com & www.nseindia.com) and Company's website (www.sequent.in).

For Viyash Scientific Limited
(Formerly known as Sequent Scientific Limited)Dr. Hari Babu Bodepudi
Managing Director and Gr CEO
DIN 01119687

Hyderabad, 05 February 2026

SMARTLINK HOLDINGS LIMITED

CIN : L26109GA1993PLC001341

Registered office: L-7, Verna Industrial Estate, Verna, Goa - 403 722

Website: www.smartlinkholdings.comEXTRACT OF STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025

₹ in Lakhs

Particulars	3 months ended 31.12.2025 (Unaudited)	3 months ended 30.09.2025 (Unaudited)	3 months ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2025 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
Total income from operations (net)	6,578.68	7,257.01	5,641.50	17,868.71	15,793.41	22,643.64
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	278.46	271.38	181.44	835.76	294.74	533.17
Net Profit / (Loss) for the period (after Exceptional and/or Extraordinary items before tax)	278.46	271.38	181.44	835.76	294.74	533.17
Net Profit / (Loss) after taxes, after extraordinary items	223.92	186.33	254.33	627.76	276.95	660.51
Total Comprehensive income for the period	249.12	179.04	251.74	638.37	261.65	603.89
Equity Share Capital	199.50	199.50	199.50	199.50	199.50	199.50
Reserves (excluding Revaluation Reserve as shown in Balance Sheet of previous year)	N.A.	N.A.	N.A.	N.A.	N.A.	19,432.00
Earnings per share (before extraordinary items) (of ₹ 2/- each)						
Basic and Diluted	2.24	1.87	2.55	6.29	2.78	6.62
Earnings per share (after extraordinary items) (of ₹ 2/- each)						
Basic and Diluted	2.24	1.87	2.55	6.29	2.78	6.62

Key standalone financial information is given below:

Particulars	3 months ended 31.12.2025 (Unaudited)	3 months ended 30.09.2025 (Unaudited)	3 months ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2025 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
Income from Operations	2,518.95	2,852.98	2,961.22	7,249.45	6,751.39	9,696.51
Profit / (Loss) Before Tax	(120.87)	(48.76)	42.88	(151.76)	22.90	(35.46)
Profit / (Loss) After Tax	(81.81)	(38.60)	150.24	(108.47)	79.58	253.68
Total Comprehensive income for the period	(68.21)	(43.09)	150.46	(103.85)	72.70	217.80

Notes :

- The above unaudited Standalone and Consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 06, 2026. The Statutory Auditors have carried out a limited review on the financial results and have expressed an unmodified conclusion thereon.
- The Company is no more a Non-banking financial Company. The Company operates in one primary segment i.e. Networking/ IT Products.
- The above is an extract of the detailed format of Quarterly and nine months ended Financial Results filed with Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange websites. The same can be accessed by scanning the QR code provided below.

<https://www.bseindia.com/xml-data/corpfilng/AttachLive/f69264fb-e3d6-4f2a-bb91-65153130bc72.pdf>

https://nsearchives.nseindia.com/corporate/SMArtlink_06022026131135_Smartlink_Outcome_of_Board_Meeting_06022026.pdf



For and on behalf of the Board

K. R. Naik
Executive Chairman
DIN: 00002013

SKF INDIA LIMITED

CIN: L29130PN1961PLC213113

Registered Address: Chinchwad, Pune 411033 Maharashtra, India

Tel. No.: 91 - 20 66112500 | E-mail: investorIndia@SKF.com | Website: www.skf.com/in/investors/skf-india-ltd

FY25-26: Quarter - October 2025 to December 2025

Revenue Growth (Standalone)	Revenue Growth (Standalone)	PBT Growth (Standalone)	PBT Growth (Standalone)
<tr



VIYASH SCIENTIFIC LIMITED (Formerly known as Sequent Scientific Limited)

Regd. Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, Road No. 6, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana, India.
E-mail: investorrelations@sequent.in, E-mail: info@viyash.com, Website: www.sequent.in Tel No.: +91 40 23635000 CIN: L99999TS1985PLC196357

EXTRACT OF THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

₹ in Lakhs

Particulars	3 months ended 31-Dec-2025	Preceding 3 months ended 30-Sep-2025	Corresponding 3 months ended in previous period 31-Dec-2024	Year to date for current period ended 31-Dec-2025	Corresponding year to date for previous period 31-Dec-2025	Previous year ended 31-Mar-2025
	Unaudited	Unaudited (Restated) (refer note 2)	Unaudited (Restated) (refer note 2)	Unaudited	Unaudited (Restated) (refer note 2)	Audited (Restated) (refer note 2)
Revenue from operations	8,584.10	8,503.00	7,740.30	25,003.50	22,345.30	30,068.40
Profit before tax and exceptional items	1,143.30	1,040.70	273.70	2,679.90	570.50	947.40
Profit before tax and after exceptional items	730.70	1,023.70	244.80	2,237.80	498.40	131.80
Profit after tax	485.20	729.00	419.40	1,582.70	479.50	157.70
Total comprehensive income / (loss), net of tax	514.30	1,033.70	(123.30)	2,261.50	(156.30)	308.00
Equity share capital	872.20	503.30	500.50	872.20	500.50	500.60
Other equity						23,815.30
Earnings per equity share: (face value of ₹ 2 each) (not annualised)	0.89	1.28	1.04	2.91	1.15	0.54
Basic (in ₹)	0.87	1.26	1.01	2.87	1.13	0.53
Diluted (in ₹)						

SUMMARIZED UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

₹ in Lakhs

Particulars	3 months ended 31-Dec-2025	Preceding 3 months ended 30-Sep-2025	Corresponding 3 months ended in previous period 31-Dec-2024	Year to date for current period ended 31-Dec-2025	Corresponding year to date for previous period 31-Dec-2024	Previous year ended 31-Mar-2025
	Unaudited	Unaudited (Restated) (refer note 2)	Unaudited (Restated) (refer note 2)	Unaudited	Unaudited (Restated) (refer note 2)	Audited (Restated) (refer note 2)
Revenue from operations	3,416.40	3,397.50	3,380.50	10,095.70	9,660.20	13,103.40
Profit before tax and exceptional items	518.70	343.70	365.30	1,116.80	865.80	1,306.40
Profit before tax and after exceptional items	106.10	326.70	336.40	674.70	793.70	491.70
Profit / (loss) after tax	(0.80)	228.40	511.30	406.60	778.60	584.90
Total comprehensive income / (loss), net of tax	(3.30)	229.00	511.00	398.80	791.90	581.70

1. The above information has been extracted from the detailed financial results for the quarter and nine months ended 31 December 2025 which have been reviewed by the Audit Committee and approved by the Board of Directors and filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. The Board of Directors of the Company at their meeting held on 26 September 2024 have approved the Composite Scheme of Amalgamation (the 'Scheme') amongst the Company, erstwhile Sequent Research Limited (wholly owned subsidiary of the Company), Viyash Life Sciences Private Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Apco Labs Private Limited, Vindhya Pharma (India) Private Limited, SV Labs Private Limited, Vindhya Organics Private Limited, Genin Life Sciences Private Limited (referred to as 'transferee Companies') in terms of Section 230-232 and other applicable provisions of Companies Act, 2013.

The Hon'ble National Company Law Tribunal (NCLT), Hyderabad vide its order dated 18 November 2025 sanctioned the Scheme with an Appointed date of 01 April 2025. The Scheme has become effective on 16 December 2025 upon filing of the certified true copy of the order with the Registrar of Companies Hyderabad. The effect of the Scheme has been given in the financial results for the quarter and nine months ended 31 December 2025. As per the terms of the Scheme, the Company has allotted 18,19,21,827 fully paid-up equity shares of face value of ₹ 2 each, as per the share exchange ratio of 56 fully paid-up equity shares of face value of ₹ 2 each of the Company for every 100 fully paid-up equity shares of face value of ₹ 10 each held by eligible shareholders of erstwhile Viyash Life Sciences Private Limited as on the record date. The Company has also allotted 2,03,41,257 warrants under the Scheme to eligible warrant holders of erstwhile Viyash Life Sciences Private Limited and received a consideration of ₹ 925 million during the quarter ended 31 December 2025 (representing 25% on Warrant consideration as per the Scheme).

The Company has accounted for the business combination transaction using the 'Pooling of interest method' as given under Appendix C to Ind AS 103, 'Business Combinations of Entities under Common Control', in accordance with the accounting treatment prescribed in the Scheme. Accordingly, the financial results in respect of the preceding / corresponding prior periods have been restated as if the aforesaid business combination had occurred from the beginning of the preceding period i.e. 01 April 2024.

3. The full format of the financial results for the quarter and nine months ended 31 December 2025 are available on the Stock Exchange websites (www.bseindia.com and www.nseindia.com) and Company's website (www.sequent.in).

For Viyash Scientific Limited
(Formerly known as Sequent Scientific Limited)Dr. Hari Babu Bodepudi
Managing Director and Gr CEO
DIN 01119687

Hyderabad, 05 February 2026

SMARTLINK HOLDINGS LIMITED

CIN : L26109GA1993PLC001341

Registered office: L-7, Verna Industrial Estate, Verna, Goa - 403 722

Website: www.smartlinkholdings.comEXTRACT OF STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025

₹ in Lakhs

Particulars	3 months ended 31.12.2025 (Unaudited)	3 months ended 30.09.2025 (Unaudited)	3 months ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2025 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
Total income from operations (net)	6,578.68	7,257.01	5,641.50	17,868.71	15,793.41	22,643.64
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	278.46	271.38	181.44	835.76	294.74	533.17
Net Profit / (Loss) for the period (after Exceptional and/or Extraordinary items before tax)	278.46	271.38	181.44	835.76	294.74	533.17
Net Profit / (Loss) after taxes, after extraordinary items	223.92	186.33	254.33	627.76	276.95	660.51
Total Comprehensive income for the period	249.12	179.04	251.74	638.37	261.65	603.89
Equity Share Capital	199.50	199.50	199.50	199.50	199.50	199.50
Reserves (excluding Revaluation Reserve as shown in Balance Sheet of previous year)	N.A.	N.A.	N.A.	N.A.	N.A.	19,432.00
Earnings per share (before extraordinary items) (of ₹ 2/- each)						
Basic and Diluted	2.24	1.87	2.55	6.29	2.78	6.62
Earnings per share (after extraordinary items) (of ₹ 2/- each)						
Basic and Diluted	2.24	1.87	2.55	6.29	2.78	6.62

Key standalone financial information is given below:

Particulars	3 months ended 31.12.2025 (Unaudited)	3 months ended 30.09.2025 (Unaudited)	3 months ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2025 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
Income from Operations	2,518.95	2,852.98	2,961.22	7,249.45	6,751.39	9,696.51
Profit / (Loss) Before Tax	(120.87)	(48.76)	42.88	(151.76)	22.90	(35.46)
Profit / (Loss) After Tax	(81.81)	(38.60)	150.24	(108.47)	79.58	253.68
Total Comprehensive income for the period	(68.21)	(43.09)	150.46	(103.85)	72.70	217.80

Notes :

- The above unaudited Standalone and Consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 06, 2026. The Statutory Auditors have carried out a limited review on the financial results and have expressed an unmodified conclusion thereon.
- The Company is no more a Non-banking financial Company. The Company operates in one primary segment i.e. Networking/ IT Products.
- The above is an extract of the detailed format of Quarterly and nine months ended Financial Results filed with Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange websites. The same can be accessed by scanning the QR code provided below.

<https://www.bseindia.com/xml-data/corpfilng/AttachLive/f69264fb-e3d6-4f2a-bb91-65153130bc72.pdf>

https://nsearchives.nseindia.com/corporate/SMARTLINK_06022026131135_Smartlink_Outcome_of_Board_Meeting_06022026.pdf



For and on behalf of the Board

K. R. Naik
Executive Chairman
DIN: 00002013

SKF INDIA LIMITED

CIN: L29130PN1961PLC213113

Registered Address: Chinchwad, Pune 411033 Maharashtra, India

Tel. No.: 91 - 20 66112500 | E-mail: investorIndia@SKF.com | Website: www.skf.com/in/investors/skf-india-ltd

FY25-26: Quarter - October 2025 to December 2025

| Revenue Growth (Standalone) | Revenue Growth (Standalone) | PBT Growth (Standalone) | PBT Growth (Standalone) |
</tr
| --- | --- | --- | --- |



VIYASH SCIENTIFIC LIMITED (Formerly known as Sequent Scientific Limited)

Regd. Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, Road No. 6, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana, India.
E-mail: investorrelations@sequent.in, E-mail: info@viyash.com, Website: www.sequent.in Tel No.: +91 40 23635000 CIN: L99999TS1985PLC196357

EXTRACT OF THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

₹ in Lakhs)

Particulars	3 months ended 31-Dec-2025	Preceding 3 months ended 30-Sep-2025	Corresponding 3 months ended in previous period 31-Dec-2024	Year to date for current period ended 31-Dec-2025	Corresponding year to date for previous period 31-Dec-2025	Previous year ended 31-Mar-2025
	Unaudited	Unaudited (Restated) (refer note 2)	Unaudited (Restated) (refer note 2)	Unaudited	Unaudited (Restated) (refer note 2)	Audited (Restated) (refer note 2)
Revenue from operations	8,584.10	8,503.00	7,740.30	25,003.50	22,345.30	30,068.40
Profit before tax and exceptional items	1,143.30	1,040.70	273.70	2,679.90	570.50	947.40
Profit before tax and after exceptional items	730.70	1,023.70	244.80	2,237.80	498.40	131.80
Profit after tax	485.20	729.00	419.40	1,582.70	479.50	157.70
Total comprehensive income / (loss), net of tax	514.30	1,033.70	(123.30)	2,261.50	(156.30)	308.00
Equity share capital	872.20	503.30	500.50	872.20	500.50	500.60
Other equity						23,815.30
Earnings per equity share: (face value of ₹ 2 each) (not annualised)	0.89	1.28	1.04	2.91	1.15	0.54
Basic (in ₹)	0.87	1.26	1.01	2.87	1.13	0.53
Diluted (in ₹)						

SUMMARIZED UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

₹ in Lakhs)

Particulars	3 months ended 31-Dec-2025	Preceding 3 months ended 30-Sep-2025	Corresponding 3 months ended in previous period 31-Dec-2024	Year to date for current period ended 31-Dec-2025	Corresponding year to date for previous period 31-Dec-2024	Previous year ended 31-Mar-2025
	Unaudited	Unaudited (Restated) (refer note 2)	Unaudited (Restated) (refer note 2)	Unaudited	Unaudited (Restated) (refer note 2)	Audited (Restated) (refer note 2)
Revenue from operations	3,416.40	3,397.50	3,380.50	10,095.70	9,660.20	13,103.40
Profit before tax and exceptional items	518.70	343.70	365.30	1,116.80	865.80	1,306.40
Profit before tax and after exceptional items	106.10	326.70	336.40	674.70	793.70	491.70
Profit / (loss) after tax	(0.80)	228.40	511.30	406.60	778.60	584.90
Total comprehensive income / (loss), net of tax	(3.30)	229.00	511.00	398.80	791.90	581.70

*1. The above information has been extracted from the detailed financial results for the quarter and nine months ended 31 December 2025 which have been reviewed by the Audit Committee and approved by the Board of Directors and filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. The Board of Directors of the Company at their meeting held on 26 September 2024 have approved the Composite Scheme of Amalgamation (the 'Scheme') amongst the Company, erstwhile Sequent Research Limited (wholly owned subsidiary of the Company), Viyash Life Sciences Private Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Apocure Labs Private Limited, Vindhya Pharma (India) Private Limited, SV Labs Private Limited, Vindhya Organics Private Limited, Genin Life Sciences Private Limited (referred to as 'transferee Companies') in terms of Section 230-232 and other applicable provisions of Companies Act, 2013.

The Hon'ble National Company Law Tribunal (NCLT), Hyderabad vide its order dated 18 November 2025 sanctioned the Scheme with an Appointed date of 01 April 2025. The Scheme has become effective on 16 December 2025 upon filing of the certified true copy of the order with the Registrar of Companies Hyderabad. The effect of the Scheme has been given in the financial results for the quarter and nine months ended 31 December 2025. As per the terms of the Scheme, the Company has allotted 18,19,21,827 fully paid-up equity shares of face value of ₹ 2 each, as per the share exchange ratio of 56 fully paid-up equity shares of face value of ₹ 2 each of the Company to 100 fully paid-up equity shares of face value of ₹ 10 each held by eligible shareholders of erstwhile Viyash Life Sciences Private Limited as on the record date. The Company has also allotted 2,03,41,257 warrants under the Scheme to eligible warrant holders of erstwhile Viyash Life Sciences Private Limited and received a consideration of ₹ 925 million during the quarter ended 31 December 2025 (representing 25% on Warrant consideration as per the Scheme).

The Company has accounted for the business combination transaction using the 'Pooling of interest method' as given under Appendix C to Ind AS 103, 'Business Combinations of Entities under Common Control', in accordance with the accounting treatment prescribed in the Scheme. Accordingly, the financial results in respect of the preceding / corresponding prior periods have been restated as if the aforesaid business combination had occurred from the beginning of the preceding period i.e. 01 April 2024.

3. The full format of the financial results for the quarter and nine months ended 31 December 2025 are available on the Stock Exchange websites (www.bseindia.com & www.nseindia.com) and Company's website (www.sequent.in).

For Viyash Scientific Limited
(Formerly known as Sequent Scientific Limited)Dr. Hari Babu Bodepudi
Managing Director and Gr CEO
DIN 01119687

Hyderabad, 05 February 2026

SMARTLINK HOLDINGS LIMITED

CIN : L26109GA1993PLC001341

Registered office: L-7, Verna Industrial Estate, Verna, Goa - 403 722

Website: www.smartlinkholdings.comEXTRACT OF STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025

₹ in Lakhs)

Particulars	3 months ended 31.12.2025 (Unaudited)	3 months ended 30.09.2025 (Unaudited)	3 months ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2025 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
Total income from operations (net)	6,578.68	7,257.01	5,641.50	17,868.71	15,793.41	22,643.64
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	278.46	271.38	181.44	835.76	294.74	533.17
Net Profit / (Loss) for the period (after Exceptional and/or Extraordinary items before tax)	278.46	271.38	181.44	835.76	294.74	533.17
Net Profit / (Loss) after taxes, after extraordinary items	223.92	186.33	254.33	627.76	276.95	660.51
Total Comprehensive income for the period	249.12	179.04	251.74	638.37	261.65	603.89
Equity Share Capital	199.50	199.50	199.50	199.50	199.50	199.50
Reserves (excluding Revaluation Reserve as shown in Balance Sheet of previous year)	N.A.	N.A.	N.A.	N.A.	N.A.	19,432.00
Earnings per share (before extraordinary items) (of ₹ 2/- each)						
Basic and Diluted	2.24	1.87	2.55	6.29	2.78	6.62
Earnings per share (after extraordinary items) (of ₹ 2/- each)						
Basic and Diluted	2.24	1.87	2.55	6.29	2.78	6.62

Key standalone financial information is given below:

Particulars	3 months ended 31.12.2025 (Unaudited)	3 months ended 30.09.2025 (Unaudited)	3 months ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2025 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
Income from Operations	2,518.95	2,852.98	2,961.22	7,249.45	6,751.39	9,696.51
Profit / (Loss) Before Tax	(120.87)	(48.76)	42.88	(151.76)	22.90	(35.46)
Profit / (Loss) After Tax	(81.81)	(38.60)	150.24	(108.47)	79.58	253.68
Total Comprehensive income for the period	(68.21)	(43.09)	150.46	(103.85)	72.70	217.80

Notes :

- The above unaudited Standalone and Consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 06, 2026. The Statutory Auditors have carried out a limited review on the financial results and have expressed an unmodified conclusion thereon.
- The Company is no more a Non-banking financial Company. The Company operates in one primary segment i.e. Networking/ IT Products.
- The above is an extract of the detailed format of Quarterly and nine months ended Financial Results filed with Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange websites. The same can be accessed by scanning the QR code provided below.

<https://www.bseindia.com/xml-data/corpfilng/AttachLive/f69264fb-e3d6-4f2a-bb91-65153130bc72.pdf>

https://nsearchives.nseindia.com/corporate/SMARTLINK_06022026131135_Smartlink_Outcome_of_Board_Meeting_06022026.pdf



For and on behalf of the Board

K. R. Naik
Executive Chairman
DIN: 00002013

SKF INDIA LIMITED

CIN: L29130PN1961PLC213113

Registered Address: Chinchwad, Pune 411033 Maharashtra, India

Tel. No.: 91 - 20 66112500 | E-mail: investorIndia@SKF.com | Website: www.skf.com/in/investors/skf-india-ltd

FY25-26: Quarter - October 2025 to December 2025

Revenue Growth (Standalone)	Revenue Growth (Standalone)	PBT Growth (Standalone)	PBT Growth (Standalone)



VIYASH SCIENTIFIC LIMITED (Formerly known as Sequent Scientific Limited)

Regd. Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, Road No. 6, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana, India.
E-mail: investorrelations@sequent.in, E-mail: info@viyash.com, Website: www.sequent.in Tel No.: +91 40 23635000 CIN: L99999TS1985PLC196357

EXTRACT OF THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

₹ in Lakhs

Particulars	3 months ended 31-Dec-2025	Preceding 3 months ended 30-Sep-2025	Corresponding 3 months ended in previous period 30-Dec-2024	Year to date for current period ended 31-Dec-2025	Corresponding year to date for previous period 31-Dec-2025	Previous year ended 31-Mar-2025
	Unaudited	Unaudited (Restated) (refer note 2)	Unaudited (Restated) (refer note 2)	Unaudited	Unaudited (Restated) (refer note 2)	Audited (Restated) (refer note 2)
Revenue from operations	8,584.10	8,503.00	7,740.30	25,003.50	22,345.30	30,068.40
Profit before tax and exceptional items	1,143.30	1,040.70	273.70	2,679.90	570.50	947.40
Profit before tax and after exceptional items	730.70	1,023.70	244.80	2,237.80	498.40	131.80
Profit after tax	485.20	729.00	419.40	1,582.70	479.50	157.70
Total comprehensive income / (loss), net of tax	514.30	1,033.70	(123.30)	2,261.50	(156.30)	308.00
Equity share capital	872.20	503.30	500.50	872.20	500.50	500.60
Other equity						23,815.30
Earnings per equity share: (face value of ₹ 2 each) (not annualised)	0.89	1.28	1.04	2.91	1.15	0.54
Basic (in ₹)	0.87	1.26	1.01	2.87	1.13	0.53

SUMMARIZED UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

₹ in Lakhs

Particulars	3 months ended 31-Dec-2025	Preceding 3 months ended 30-Sep-2025	Corresponding 3 months ended in previous period 31-Dec-2024	Year to date for current period ended 31-Dec-2025	Corresponding year to date for previous period 31-Dec-2024	Previous year ended 31-Mar-2025
	Unaudited	Unaudited (Restated) (refer note 2)	Unaudited (Restated) (refer note 2)	Unaudited	Unaudited (Restated) (refer note 2)	Audited (Restated) (refer note 2)
Revenue from operations	3,416.40	3,397.50	3,380.50	10,095.70	9,660.20	13,103.40
Profit before tax and exceptional items	518.70	343.70	365.30	1,116.80	865.80	1,306.40
Profit before tax and after exceptional items	106.10	326.70	336.40	674.70	793.70	491.70
Profit / (loss) after tax	(0.80)	228.40	511.30	406.60	778.60	584.90
Total comprehensive income / (loss), net of tax	(3.30)	229.00	511.00	398.80	791.90	581.70

*1. The above information has been extracted from the detailed financial results for the quarter and nine months ended 31 December 2025 which have been reviewed by the Audit Committee and approved by the Board of Directors and filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. The Board of Directors of the Company at their meeting held on 26 September 2024 have approved the Composite Scheme of Amalgamation (the 'Scheme') amongst the Company, erstwhile Sequent Research Limited (wholly owned subsidiary of the Company), Viyash Life Sciences Private Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Apocure Labs Private Limited, Vindhya Pharma (India) Private Limited, SV Labs Private Limited, Vindhya Organics Private Limited, Genin Life Sciences Private Limited (referred to as 'transferee Companies') in terms of Section 230-232 and other applicable provisions of Companies Act, 2013.

The Hon'ble National Company Law Tribunal (NCLT), Hyderabad vide its order dated 18 November 2025 sanctioned the Scheme with an Appointed date of 01 April 2025. The Scheme has become effective on 16 December 2025 upon filing of the certified true copy of the order with the Registrar of Companies Hyderabad. The effect of the Scheme has been given in the financial results for the quarter and nine months ended 31 December 2025. As per the terms of the Scheme, the Company has allotted 18,19,21,827 fully paid-up equity shares of face value of ₹ 2 each, as per the share exchange ratio of 56 fully paid-up equity shares of face value of ₹ 2 each of the Company for every 100 fully paid-up equity shares of face value of ₹ 10 each held by eligible shareholders of erstwhile Viyash Life Sciences Private Limited as on the record date. The Company has also allotted 2,03,41,257 warrants under the Scheme to eligible warrant holders of erstwhile Viyash Life Sciences Private Limited and received a consideration of ₹ 925 million during the quarter ended 31 December 2025 (representing 25% on Warrant consideration as per the Scheme).

The Company has accounted for the business combination transaction using the 'Pooling of interest method' as given under Appendix C to Ind AS 103, 'Business Combinations of Entities under Common Control', in accordance with the accounting treatment prescribed in the Scheme. Accordingly, the financial results in respect of the preceding/ corresponding prior periods have been restated as if the aforesaid business combination had occurred from the beginning of the preceding period i.e. 01 April 2024.

3. The full format of the financial results for the quarter and nine months ended 31 December 2025 are available on the Stock Exchange websites (www.bseindia.com & www.nseindia.com) and Company's website (www.sequent.in).

For Viyash Scientific Limited
(Formerly known as Sequent Scientific Limited)Dr. Hari Babu Bodepudi
Managing Director and Gr CEO
DIN 01119687

Hyderabad, 05 February 2026



We move people further

Efficient automotive solutions that
keep the world moving



Since 1907 we have been designing and producing precision components and systems that keep vehicles efficient and durable. Today, we are focussed on extending the life of mobility and innovating a smooth future. From the smallest bearings to powertrains, we are here to help the world's leading vehicle manufacturers and aftermarket partners stay ahead of the curve.

Scan the QR code
to view the Financial
ResultsScan the QR code
to view the outcome of the
board meetingScan the QR code
to view the results on BSEScan the QR code
to view the results on NSE

SMARTLINK HOLDINGS LIMITED

CIN : L26109GA1993PLC001341

Registered office: L-7, Verna Industrial Estate, Verna, Goa - 403 722

Website: www.smartlinkholdings.comEXTRACT OF STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025

₹ in Lakhs

Particulars	3 months ended 31.12.2025 (Unaudited)	3 months ended 30.09.2025 (Unaudited)	3 months ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2025 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
Total income from operations (net)	6,578.68	7,257.01	5,641.50	17,868.71	15,793.41	22,643.64
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	278.46	271.38	181.44	835.76	294.74	533.17
Net Profit / (Loss) for the period (after Exceptional and/or Extraordinary items before tax)	278.46	271.38	181.44	835.76	294.74	533.17
Net Profit / (Loss) after taxes, after extraordinary items	223.92	186.33	254.33	627.76	276.95	660.51
Total Comprehensive income for the period	249.12	179.04	251.74	638.37	261.65	603.89
Equity Share Capital	199.50	199.50	199.50	199.50	199.50	199.50
Reserves (excluding Revaluation Reserve as shown in Balance Sheet of previous year)	N.A.	N.A.	N.A.	N.A.	N.A.	19,432.00
Earnings per share (before extraordinary items) (of ₹ 2/- each)						
Basic and Diluted	2.24	1.87	2.55	6.29	2.78	6.62
Earnings per share (after extraordinary items) (of ₹ 2/- each)						
Basic and Diluted	2.24	1.87	2.55	6.29	2.78	6.62

Key standalone financial information is given below:

Particulars	3 months ended 31.12.2025 (Unaudited)	3 months ended 30.09.2025 (Unaudited)	3 months ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2025 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
Income from Operations	2,518.95	2,852.98	2,961.22	7,249.45	6,751.39	9,696.51
Profit / (Loss) Before Tax	(120.87)	(48.76)	42.88	(151.76)	22.90	(35.46)
Profit / (Loss) After Tax	(81.81)	(38.60)	150.24	(108.47)	79.58	253.68
Total Comprehensive income for the period	(68.21)	(43.09)	150.46	(103.85)	72.70	217.80

Notes :

- The above unaudited Standalone and Consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 06, 2026. The Statutory Auditors have carried out a limited review on the financial results and have expressed an unmodified conclusion thereon.
- The Company is no more a Non-banking financial Company. The Company operates in one primary segment i.e. Networking/ IT Products.
- The above is an extract of the detailed format of Quarterly and nine months ended Financial Results filed with Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange websites. The same can be accessed by scanning the QR code provided below.

<https://www.bseindia.com/xml-data/corpfilng/AttachLive/f69264fb-e3d6-4f2a-bb91-65153130bc72.pdf>


VIYASH SCIENTIFIC LIMITED (Formerly known as Sequent Scientific Limited)

Regd. Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, Road No. 6, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana, India.
E-mail: investorrelations@sequent.in, E-mail: info@viyash.com, Website: www.sequent.in Tel No.: +91 40 23635000 CIN: L99999TS1985PLC196357

EXTRACT OF THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

(₹ in Lakhs)

Particulars	3 months ended 31-Dec-2025	Preceding 3 months ended 30-Sep-2025	Corresponding 3 months ended in previous period 30-Dec-2024	Year to date for current period ended 31-Dec-2025	Corresponding year to date for previous period 31-Dec-2025	Previous year ended 31-Mar-2025
	Unaudited	Unaudited (Restated) (refer note 2)	Unaudited (Restated) (refer note 2)	Unaudited	Unaudited (Restated) (refer note 2)	Audited (Restated) (refer note 2)
Revenue from operations	8,584.10	8,503.00	7,740.30	25,003.50	22,345.30	30,068.40
Profit before tax and exceptional items	1,143.30	1,040.70	273.70	2,679.90	570.50	947.40
Profit before tax and after exceptional items	730.70	1,023.70	244.80	2,237.80	498.40	131.80
Profit after tax	485.20	729.00	419.40	1,582.70	479.50	157.70
Total comprehensive income / (loss), net of tax	514.30	1,033.70	(123.30)	2,261.50	(156.30)	308.00
Equity share capital	872.20	503.30	500.50	872.20	500.50	500.60
Other equity						23,815.30
Earnings per equity share: (face value of ₹ 2 each) (not annualised)	0.89	1.28	1.04	2.91	1.15	0.54
Basic (in ₹)	0.87	1.26	1.01	2.87	1.13	0.53
Diluted (in ₹)						

SUMMARIZED UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

(₹ in Lakhs)

Particulars	3 months ended 31-Dec-2025	Preceding 3 months ended 30-Sep-2025	Corresponding 3 months ended in previous period 31-Dec-2024	Year to date for current period ended 31-Dec-2025	Corresponding year to date for previous period 31-Dec-2024	Previous year ended 31-Mar-2025
	Unaudited	Unaudited (Restated) (refer note 2)	Unaudited (Restated) (refer note 2)	Unaudited	Unaudited (Restated) (refer note 2)	Audited (Restated) (refer note 2)
Revenue from operations	3,416.40	3,397.50	3,380.50	10,095.70	9,660.20	13,103.40
Profit before tax and exceptional items	518.70	343.70	365.30	1,116.80	865.80	1,306.40
Profit before tax and after exceptional items	106.10	326.70	336.40	674.70	793.70	491.70
Profit / (Loss) after tax	(0.80)	228.40	511.30	400.60	778.60	584.90
Total comprehensive income / (loss), net of tax	(3.30)	229.00	511.00	398.80	791.90	581.70

*1. The above information has been extracted from the detailed financial results for the quarter and nine months ended 31 December 2025 which have been reviewed by the Audit Committee and approved by the Board of Directors and filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. The Board of Directors of the Company at their meeting held on 26 September 2024 have approved the Composite Scheme of Amalgamation (the 'Scheme') amongst the Company, erstwhile Sequent Research Limited (wholly owned subsidiary of the Company), Viyash Life Sciences Private Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, SV Labs Private Limited, Vindhya Organics Private Limited, Genin Life Sciences Private Limited (referred to as transferor Companies) in terms of Section 230-232 and other applicable provisions of Companies Act, 2013.

The Hon'ble National Company Law Tribunal (NCLT), Hyderabad vide its order dated 18 November 2025 sanctioned the Scheme with an Appointed date of 01 April 2025. The Scheme has become effective on 16 December 2025 upon filing of the certified true copy of the order with the Registrar of Companies Hyderabad. The effect of the Scheme has been given in the financial results for the quarter and nine months ended 31 December 2025. As per the terms of the Scheme, the Company has allotted 18,19,21,827 fully paid-up equity shares of face value of ₹ 2 each, as per the share exchange ratio of 56 fully paid-up equity shares of face value of ₹ 2 each of the Company for every 100 fully paid-up equity shares of face value of ₹ 10 each held by eligible shareholders of erstwhile Viyash Life Sciences Private Limited as on the record date. The Company has also allotted 2,03,41,257 warrants under the Scheme to eligible warrant holder of erstwhile Viyash Life Sciences Private Limited as per the Warrant exchange ratio of 56 warrants of the Company for every 100 warrants held in erstwhile Viyash Life Sciences Private Limited and received a consideration of ₹ 925 million during the quarter ended 31 December 2025 (representing 25% on Warrant consideration as per the Scheme).

The Company has accounted for the business combination transaction using the 'Pooling of interest method' as given under Appendix C to Ind AS 103, 'Business Combinations of Entities under Common Control', in accordance with the accounting treatment prescribed in the Scheme. Accordingly, the financial results in respect of the preceding / corresponding prior periods have been restated as if the aforesaid business combination had occurred from the beginning of the preceding period i.e. 01 April 2024.

3. The full format of the financial results for the quarter and nine months ended 31 December 2025 are available on the Stock Exchange websites (www.bseindia.com & www.nseindia.com) and Company's website (www.sequent.in)."



For Viyash Scientific Limited
(Formerly known as Sequent Scientific Limited)

Dr. Hari Babu Bodepudi
Managing Director and Gr CEO
DIN 01119687

Hyderabad, 05 February 2026

SMARTLINK HOLDINGS LIMITED

CIN : L26109GA1993PLC001341

Registered office: L-7, Verna Industrial Estate, Verna, Goa - 403 722

Website: www.smartlinkholdings.com
EXTRACT OF STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025

(₹ in Lakhs)

Particulars	3 months ended 31.12.2025 (Unaudited)	3 months ended 30.09.2025 (Unaudited)	3 months ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2025 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
Total income from operations (net)	6,578.68	7,257.01	5,641.50	17,868.71	15,793.41	22,643.64
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	278.46	271.38	181.44	835.76	294.74	533.17
Net Profit / (Loss) for the period (after Exceptional and/or Extraordinary items before tax)	278.46	271.38	181.44	835.76	294.74	533.17
Net Profit / (Loss) after taxes, after extraordinary items	223.92	186.33	254.33	627.76	276.95	660.51
Total Comprehensive income for the period	249.12	179.04	251.74	638.37	261.65	603.89
Equity Share Capital	199.50	199.50	199.50	199.50	199.50	199.50
Reserves (excluding Revaluation Reserve as shown in Balance Sheet of previous year)	N.A.	N.A.	N.A.	N.A.	N.A.	19,432.00
Earnings per share (before extraordinary items) (of ₹ 2/- each)	2.24	1.87	2.55	6.29	2.78	6.62
Basic and Diluted	2.24	1.87	2.55	6.29	2.78	6.62
Earnings per share (after extraordinary items) (of ₹ 2/- each)	2.24	1.87	2.55	6.29	2.78	6.62
Basic and Diluted	2.24	1.87	2.55	6.29	2.78	6.62

Key standalone financial information is given below:

Particulars	3 months ended 31.12.2025 (Unaudited)	3 months ended 30.09.2025 (Unaudited)	3 months ended 31.12.2024 (Unaudited)	Nine months ended 31.12.2025 (Unaudited)	Nine months ended 31.12.2024 (Unaudited)	Year ended 31.03.2025 (Audited)
Income from Operations	2,518.95	2,852.98	2,961.22	7,249.45	6,751.39	9,696.51
Profit / (Loss) Before Tax	(120.87)	(48.76)	42.88	(151.76)	22.90	(35.46)
Profit / (Loss) After Tax	(81.81)	(38.60)	150.24	(108.47)	79.58	253.68
Total Comprehensive income for the period	(68.21)	(43.09)	150.46	(103.85)	72.70	217.80

Notes :

- The above unaudited Standalone and Consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 06, 2026. The Statutory Auditors have carried out a limited review on the financial results and have expressed an unmodified conclusion thereon.
- The Company is no more a Non-banking financial Company. The Company operates in one primary segment i.e. Networking/ IT Products.
- The above is an extract of the detailed format of Quarterly and nine months ended Financial Results filed with Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange websites. The same can be accessed by scanning the QR code provided below.

<https://www.bseindia.com/xml-data/corpfilng/AttachLive/f69264fb-e3d6-4f2a-bb91-65153130bc72.pdf>

https://nsearchives.nseindia.com/corporate/SMARTLINK_06022026131135_Smartlink_Outcome_of_Board_Meeting_06022026.pdf



For and on behalf of the Board

K. R. Naik
Executive Chairman
DIN: 00002013

SKF INDIA LIMITED

CIN: L29130PN1961PLC213113

Registered Address: Chinchwad, Pune 411033 Maharashtra, India

Tel. No.: 91 - 20 66112500 | E-mail: investorIndia@SKF.com | Website: www.skf.com/in/investors/skf-india-ltd

FY25-26

